{
 "name": "FDA catalyst calendar, next 30 days",
 "url": "https://sec-api.dev/fda-calendar",
 "license": {
  "name": "CC BY 4.0",
  "url": "https://creativecommons.org/licenses/by/4.0/",
  "terms": "https://sec-api.dev/biotech/license.txt"
 },
 "attribution": "sec-api.dev biotech catalyst calendar (https://sec-api.dev/fda-calendar)",
 "disclaimer": "Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.",
 "snapshot": "20261116T112050Z",
 "generatedAt": "2026-11-16T11:20:50.990Z",
 "window": {
  "start": "2026-11-16",
  "end": "2026-12-16"
 },
 "count": 227,
 "fullHistory": {
  "note": "Records outside this window, outcomes and bulk exports are on paid plans.",
  "pricing": "https://sec-api.dev/pricing",
  "api": "https://sec-api.dev/api/v1/biotech/events"
 },
 "events": [
  {
   "id": "7487cefa9e20ed47",
   "type": "earnings",
   "dateConfidence": "exact",
   "date": "2026-11-16",
   "companyCik": "0002022416",
   "ticker": "SLXN",
   "status": "completed",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/2022416/000117891326005216/exhibit_99-1.htm",
     "accession": "0001178913-26-005216",
     "quote": "Reports Third Quarter 2026 Financial Results and",
     "fetchedAt": "2026-11-16T11:20:44.222Z",
     "filedAt": "2026-11-16",
     "form": "8-K"
    }
   ],
   "firstSeen": "2026-11-16",
   "lastSeen": "2026-11-16",
   "confidence": 0.9,
   "pageUrl": "https://sec-api.dev/companies/slxn/catalysts"
  },
  {
   "id": "nct06219941-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-17",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "azd0901",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer",
   "phase": "2",
   "sponsorName": "AstraZeneca",
   "title": "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2",
   "nctId": "NCT06219941",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06219941",
     "quote": "NCT06219941 (AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor AstraZeneca.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/azd0901"
  },
  {
   "id": "nct06894511-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-17",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "aaa617",
   "companyCik": "0001114448",
   "ticker": "NVS",
   "indication": "Metastatic Castration Resistant Prostate Cancer (mCRPC)",
   "phase": "2",
   "sponsorName": "Novartis Pharmaceuticals",
   "title": "PSMAndARPI: An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC",
   "nctId": "NCT06894511",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06894511",
     "quote": "NCT06894511 (An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/aaa617"
  },
  {
   "id": "nct05946941-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-18",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "deucravacitinib",
   "companyCik": "0000014272",
   "ticker": "BMY",
   "indication": "Sjögren's Syndrome",
   "phase": "3",
   "sponsorName": "Bristol-Myers Squibb",
   "title": "POETYK SjS-1: A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome",
   "nctId": "NCT05946941",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05946941",
     "quote": "NCT05946941 (A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/deucravacitinib"
  },
  {
   "id": "nct07230860-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-19",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "jnj-95597528",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Dermatitis, Atopic",
   "phase": "2",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "READY-AD: A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis",
   "nctId": "NCT07230860",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07230860",
     "quote": "NCT07230860 (A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/jnj-95597528"
  },
  {
   "id": "nct04634877-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-20",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "pembrolizumab",
   "companyCik": "0000310158",
   "ticker": "MRK",
   "indication": "Endometrial Neoplasms",
   "phase": "3",
   "sponsorName": "Merck Sharp & Dohme LLC",
   "title": "Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)",
   "nctId": "NCT04634877",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04634877",
     "quote": "NCT04634877 (Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/pembrolizumab"
  },
  {
   "id": "nct05851443-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-20",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "povorcitinib",
   "companyCik": "0000879169",
   "ticker": "INCY",
   "indication": "Moderate to Severe Asthma",
   "phase": "2",
   "sponsorName": "Incyte Corporation",
   "title": "A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma",
   "nctId": "NCT05851443",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05851443",
     "quote": "NCT05851443 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Incyte Corporation.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/povorcitinib"
  },
  {
   "id": "nct06577090-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-20",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "nimacimab",
   "companyCik": "0001516551",
   "ticker": "SKYE",
   "indication": "Obesity",
   "phase": "2",
   "sponsorName": "Skye Bioscience, Inc.",
   "title": "CBeyond: Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo",
   "nctId": "NCT06577090",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06577090",
     "quote": "NCT06577090 (Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Skye Bioscience, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/nimacimab"
  },
  {
   "id": "121b0a25fbfb0651",
   "type": "pdufa",
   "dateConfidence": "exact",
   "date": "2026-11-22",
   "companyCik": "0001160308",
   "ticker": "SVRA",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1160308/000119312526453535/svra-20260930.htm",
     "accession": "0001193125-26-453535",
     "quote": "The FDA determined that the Company's responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act (\"PDUFA\") target action date to November 22, 2026.",
     "fetchedAt": "2026-11-12T05:57:10.042Z",
     "filedAt": "2026-11-09",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1160308/000119312526344585/svra-20260630.htm",
     "accession": "0001193125-26-344585",
     "quote": "The FDA determined that the Company's responses to recent information requests by the Agency during their review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act (\"PDUFA\") target action date to November 22, 2026.",
     "fetchedAt": "2026-11-12T05:57:43.209Z",
     "filedAt": "2026-08-11",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1160308/000119312526219371/svra-20260331.htm",
     "accession": "0001193125-26-219371",
     "quote": "The FDA determined that the Company's responses to recent information requests by the Agency during their review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act (\"PDUFA\") date to November 22, 2026.",
     "fetchedAt": "2026-11-12T05:58:17.848Z",
     "filedAt": "2026-05-12",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1160308/000119312526219371/svra-20260331.htm",
     "accession": "0001193125-26-219371",
     "quote": "The FDA determined that the Company's responses to recent information requests by the FDA during their review constituted a major amendment to the BLA, resulting in a three-month extension of the PDUFA date to November 22, 2026.",
     "fetchedAt": "2026-11-12T05:58:17.848Z",
     "filedAt": "2026-05-12",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-05-12",
   "lastSeen": "2026-11-09",
   "confidence": 0.68,
   "pageUrl": "https://sec-api.dev/companies/svra/catalysts"
  },
  {
   "id": "e9eaca412ace39d5",
   "type": "pdufa",
   "dateConfidence": "exact",
   "date": "2026-11-22",
   "drugId": "deramiocel",
   "companyCik": "0001133869",
   "ticker": "CAPR",
   "indication": "rare diseases, today",
   "phase": "3",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm",
     "accession": "0001104659-26-125150",
     "quote": "Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026",
     "fetchedAt": "2026-11-12T05:57:06.778Z",
     "filedAt": "2026-11-10",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm",
     "accession": "0001104659-26-100071",
     "quote": "SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), from August 22, 2026 to November 22, 2026.",
     "fetchedAt": "2026-11-12T05:57:33.171Z",
     "filedAt": "2026-08-24",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm",
     "accession": "0001104659-26-125355",
     "quote": "Our Biologics License Application (\"BLA\"), as amended, for Deramiocel for the treatment of DMD is currently under review by the U.S. Food and Drug Administration (\"FDA\") for potential approval in the United States, with a current Prescription Drug User Fee Act (\"PDUFA\") target action date of November 22, 2026.",
     "fetchedAt": "2026-11-12T05:57:06.772Z",
     "filedAt": "2026-11-10",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm",
     "accession": "0001104659-26-125355",
     "quote": "Our BLA for Deramiocel remains under FDA review, with a PDUFA target action date of November 22, 2026.",
     "fetchedAt": "2026-11-12T05:57:06.772Z",
     "filedAt": "2026-11-10",
     "form": "10-Q"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1133869/000110465926100071/capr-20260824xex99d1.htm",
     "accession": "0001104659-26-100071",
     "quote": "- New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication -",
     "fetchedAt": "2026-11-12T05:57:33.171Z",
     "filedAt": "2026-08-24",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1133869/000110465926125355/capr-20260930x10q.htm",
     "accession": "0001104659-26-125355",
     "quote": "The FDA also extended the PDUFA target action date to November 22, 2026.",
     "fetchedAt": "2026-11-12T05:57:06.772Z",
     "filedAt": "2026-11-10",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-08-24",
   "lastSeen": "2026-11-10",
   "confidence": 0.96,
   "pageUrl": "https://sec-api.dev/pdufa/deramiocel"
  },
  {
   "id": "nct06567782-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-23",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "dostarlimab",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Neoplasms, Colon",
   "phase": "2",
   "sponsorName": "GlaxoSmithKline",
   "title": "AZUR-4: A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer",
   "nctId": "NCT06567782",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06567782",
     "quote": "NCT06567782 (A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/dostarlimab"
  },
  {
   "id": "nct06693895-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-23",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "pcv-20",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Chickenpox",
   "phase": "3",
   "sponsorName": "GlaxoSmithKline",
   "title": "A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age",
   "nctId": "NCT06693895",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06693895",
     "quote": "NCT06693895 (A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/pcv-20"
  },
  {
   "id": "nct07596199-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-23",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "dtpa",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Diphtheria-Tetanus-acellular Pertussis Vaccines",
   "phase": "3",
   "sponsorName": "GlaxoSmithKline",
   "title": "A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women",
   "nctId": "NCT07596199",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07596199",
     "quote": "NCT07596199 (A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/dtpa"
  },
  {
   "id": "nct06585787-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-24",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "karxt",
   "companyCik": "0000014272",
   "ticker": "BMY",
   "indication": "Alzheimer Disease",
   "phase": "3",
   "sponsorName": "Karuna Therapeutics, Inc., a Bristol Myers Squibb company",
   "title": "A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)",
   "nctId": "NCT06585787",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06585787",
     "quote": "NCT06585787 (A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/karxt"
  },
  {
   "id": "nct06616974-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-24",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "tx000045",
   "companyCik": "0001681087",
   "ticker": "TECX",
   "indication": "Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction",
   "phase": "2",
   "sponsorName": "Tectonic Therapeutic",
   "title": "A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)",
   "nctId": "NCT06616974",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06616974",
     "quote": "NCT06616974 (A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Tectonic Therapeutic.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/tx000045"
  },
  {
   "id": "0d426747301c6c8b",
   "type": "pdufa",
   "dateConfidence": "exact",
   "date": "2026-11-25",
   "drugId": "venglustat",
   "companyCik": "0001121404",
   "ticker": "SNY",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm",
     "accession": "0001121404-26-000008",
     "quote": "The target action date for the FDA decision is November 25, 2026.",
     "fetchedAt": "2026-11-12T05:57:55.777Z",
     "filedAt": "2026-07-30",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1121404/000162828026050803/exhibit992-2026halfyearman.htm",
     "accession": "0001628280-26-050803",
     "quote": "The target action date for the FDA decision is November 25, 2026.",
     "fetchedAt": "2026-11-12T05:57:55.773Z",
     "filedAt": "2026-07-30",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1121404/000119312526260613/d123884dex991.htm",
     "accession": "0001193125-26-260613",
     "quote": "The target action date for the FDA decision is November 25, 2026.",
     "fetchedAt": "2026-11-12T05:58:05.040Z",
     "filedAt": "2026-06-08",
     "form": "6-K"
    }
   ],
   "firstSeen": "2026-06-08",
   "lastSeen": "2026-07-30",
   "confidence": 0.86,
   "pageUrl": "https://sec-api.dev/pdufa/venglustat"
  },
  {
   "id": "nct07216079-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-25",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "rilzabrutinib",
   "companyCik": "0001121404",
   "ticker": "SNY",
   "indication": "Immune Thrombocytopenia",
   "phase": "3",
   "sponsorName": "Sanofi",
   "title": "Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan",
   "nctId": "NCT07216079",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07216079",
     "quote": "NCT07216079 (Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-25 (ESTIMATED); Lead Sponsor Sanofi.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/rilzabrutinib"
  },
  {
   "id": "nct03981796-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-26",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "niraparib",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Neoplasms",
   "phase": "3",
   "sponsorName": "Tesaro, Inc.",
   "title": "RUBY: A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer",
   "nctId": "NCT03981796",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT03981796",
     "quote": "NCT03981796 (A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-26 (ESTIMATED); Lead Sponsor Tesaro, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/niraparib"
  },
  {
   "id": "d3d04a31fcbfe498",
   "type": "pdufa",
   "dateConfidence": "exact",
   "date": "2026-11-27",
   "drugId": "ribitol",
   "companyCik": "0001743881",
   "ticker": "BBIO",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm",
     "accession": "0001743881-26-000033",
     "quote": "- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review.",
     "fetchedAt": "2026-11-12T05:57:20.635Z",
     "filedAt": "2026-10-29",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm",
     "accession": "0001743881-26-000033",
     "quote": "BBP-418 for LGMD2I/R9 PDUFA date set for November 27, 2026, with Priority Review U.S. launch upon FDA approval",
     "fetchedAt": "2026-11-12T05:57:20.635Z",
     "filedAt": "2026-10-29",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm",
     "accession": "0001743881-26-000033",
     "quote": "•On May 27, 2026, the FDA accepted the Company's New Drug Application (NDA) for BBP-418 and granted Priority Review, assigning a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026.",
     "fetchedAt": "2026-11-12T05:57:20.635Z",
     "filedAt": "2026-10-29",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm",
     "accession": "0001743881-26-000026",
     "quote": "BBP-418 for LGMD2I/R9 PDUFA date set for November 27, 2026 with Priority Review Launch upon FDA approval",
     "fetchedAt": "2026-11-12T05:57:43.558Z",
     "filedAt": "2026-08-10",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm",
     "accession": "0001743881-26-000026",
     "quote": "Furthermore, this was the quarter all three of our pipeline programs, BBP-418, encaleret, and infigratinib, moved from data into active regulatory review, with our first PDUFA date now set for November 27, 2026, which is a level of strategic execution and discipline I'm proud of.",
     "fetchedAt": "2026-11-12T05:57:43.558Z",
     "filedAt": "2026-08-10",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm",
     "accession": "0001743881-26-000026",
     "quote": "•On May 27, 2026, the FDA accepted the Company's New Drug Application (NDA) for BBP-418 and granted Priority Review, assigning a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026.",
     "fetchedAt": "2026-11-12T05:57:43.558Z",
     "filedAt": "2026-08-10",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_ex99-1.htm",
     "accession": "0001140361-26-022979",
     "quote": "Fee Act (PDUFA) target action date of November 27, 2026, and BridgeBio is poised to launch BBP-418 upon approval.",
     "fetchedAt": "2026-11-12T05:58:06.450Z",
     "filedAt": "2026-05-27",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm",
     "accession": "0001743881-26-000034",
     "quote": "The FDA accepted our NDA for filing, granted Priority Review and assigned a Prescription Drug User Fee Act (\"PDUFA\") target action date of November 27, 2026, for BBP-418.",
     "fetchedAt": "2026-11-12T05:57:20.625Z",
     "filedAt": "2026-10-29",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000027/bbio-20260630.htm",
     "accession": "0001743881-26-000027",
     "quote": "On May 27, 2026, the FDA accepted our NDA for filing, granted Priority Review and assigned a Prescription Drug User Fee Act (\"PDUFA\") target action date of November 27, 2026 for BBP-418.",
     "fetchedAt": "2026-11-12T05:57:43.555Z",
     "filedAt": "2026-08-10",
     "form": "10-Q"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_ex99-1.htm",
     "accession": "0001140361-26-022979",
     "quote": "- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval;",
     "fetchedAt": "2026-11-12T05:58:06.450Z",
     "filedAt": "2026-05-27",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000114036126035055/ef20081330_ex99-1.htm",
     "accession": "0001140361-26-035055",
     "quote": "The Company's approved medicine, Attruby, is available to people with transthyretin amyloid cardiomyopathy, and the Company has three additional medicines under FDA review, each for a genetic condition with limited or no approved treatment options: BBP-418 for limb-girdle muscular dystrophy type 2I/R9, or LGMD2I/R9 (PDUFA date with Priority Review: November 27, 2026); encaleret for autosomal dominant hypocalcemia type 1, or ADH1 (PDUFA date with Priority Review: May 7, 2027); and infigratinib for achondroplasia.",
     "fetchedAt": "2026-11-12T05:57:31.991Z",
     "filedAt": "2026-08-31",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260630xex991.htm",
     "accession": "0001743881-26-000026",
     "quote": "- All three planned NDAs are now submitted to the FDA: BBP-418 for LGMD2I/R9 was accepted with Priority Review (PDUFA November 27, 2026); encaleret for ADH1 was accepted with Priority Review (PDUFA May 8, 2027), with no advisory committee planned for either; oral infigratinib for achondroplasia has been submitted, with U.S. launch expected mid-2027",
     "fetchedAt": "2026-11-12T05:57:43.558Z",
     "filedAt": "2026-08-10",
     "form": "8-K"
    }
   ],
   "firstSeen": "2026-05-27",
   "lastSeen": "2026-10-29",
   "confidence": 0.96,
   "pageUrl": "https://sec-api.dev/pdufa/ribitol"
  },
  {
   "id": "nct07103148-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-28",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "yellow-fever-vaccine-live",
   "companyCik": "0001121404",
   "ticker": "SNY",
   "indication": "Yellow Fever Immunization",
   "phase": "3",
   "sponsorName": "Sanofi",
   "title": "A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population",
   "nctId": "NCT07103148",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07103148",
     "quote": "NCT07103148 (A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-28 (ESTIMATED); Lead Sponsor Sanofi.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/yellow-fever-vaccine-live"
  },
  {
   "id": "nct06641466-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-29",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "rimegepant",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Menstrual Migraine",
   "phase": "3",
   "sponsorName": "Pfizer",
   "title": "A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine",
   "nctId": "NCT06641466",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06641466",
     "quote": "NCT06641466 (A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-29 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/rimegepant"
  },
  {
   "id": "709a1320328e1f7f",
   "type": "pdufa",
   "dateConfidence": "exact",
   "date": "2026-11-30",
   "drugId": "bezuclastinib",
   "companyCik": "0001622229",
   "ticker": "COGT",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm",
     "accession": "0001193125-26-449926",
     "quote": "Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026",
     "fetchedAt": "2026-11-12T05:57:12.140Z",
     "filedAt": "2026-11-05",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm",
     "accession": "0001193125-26-449926",
     "quote": "Potential FDA approval of bezuclastinib in GIST - PDUFA date of November 30, 2026",
     "fetchedAt": "2026-11-12T05:57:12.140Z",
     "filedAt": "2026-11-05",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1622229/000119312526341315/cogt-ex99_1.htm",
     "accession": "0001193125-26-341315",
     "quote": "Potential FDA approval of bezuclastinib in GIST - PDUFA date of November 30, 2026",
     "fetchedAt": "2026-11-12T05:57:43.753Z",
     "filedAt": "2026-08-10",
     "form": "8-K"
    },
    {
     "kind": "sec_424b",
     "url": "https://www.sec.gov/Archives/edgar/data/1622229/000119312526342683/d149476d424b5.htm",
     "accession": "0001193125-26-342683",
     "quote": "In March 2026, we submitted our second NDA for bezuclastinib in combination with sunitinib for patients with GIST who have received prior treatment with imatinib under the FDA's Real-Time Oncology Review program, which the FDA accepted with Priority Review and assigned a PDUFA target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:43.746Z",
     "filedAt": "2026-08-10",
     "form": "424B5"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1622229/000119312526449963/cogt-20260930.htm",
     "accession": "0001193125-26-449963",
     "quote": "The FDA assigned a PDUFA target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:12.125Z",
     "filedAt": "2026-11-05",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1622229/000119312526342393/cogt-20260630.htm",
     "accession": "0001193125-26-342393",
     "quote": "The FDA assigned a PDUFA target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:43.747Z",
     "filedAt": "2026-08-10",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-08-10",
   "lastSeen": "2026-11-05",
   "confidence": 0.96,
   "pageUrl": "https://sec-api.dev/pdufa/bezuclastinib"
  },
  {
   "id": "d393ec0ba051d747",
   "type": "pdufa",
   "dateConfidence": "exact",
   "date": "2026-11-30",
   "drugId": "povetacicept",
   "companyCik": "0000875320",
   "ticker": "VRTX",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm",
     "accession": "0000875320-26-000287",
     "quote": "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:19.820Z",
     "filedAt": "2026-11-02",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm",
     "accession": "0000875320-26-000256",
     "quote": "•The U.S. FDA accepted the BLA submission for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:54.495Z",
     "filedAt": "2026-08-03",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm",
     "accession": "0000875320-26-000291",
     "quote": "•The biologics license application for accelerated approval of povetacicept for adults with IgAN is under priority review by the FDA, with an assigned PDUFA target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:19.298Z",
     "filedAt": "2026-11-03",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm",
     "accession": "0000875320-26-000291",
     "quote": "FDA's review of our biologics license application for accelerated approval of povetacicept with an assigned PDUFA target action date of November 30, 2026;",
     "fetchedAt": "2026-11-12T05:57:19.298Z",
     "filedAt": "2026-11-03",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/875320/000087532026000259/vrtx-20260630.htm",
     "accession": "0000875320-26-000259",
     "quote": "•The FDA accepted our biologics license application for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:53.869Z",
     "filedAt": "2026-08-04",
     "form": "10-Q"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1704292/000162828026053791/zlab-202686x8kex991.htm",
     "accession": "0001628280-26-053791",
     "quote": "•Povetacicept (pove, APRIL/BAFF): In June 2026, Zai Lab partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:50.047Z",
     "filedAt": "2026-08-06",
     "form": "8-K",
     "cik": "0001704292"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1704292/000162828026053793/zlab-20260630.htm",
     "accession": "0001628280-26-053793",
     "quote": "•Povetacicept (Pove, Anti-APRIL/BAFF): In June 2026, our partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with IgAN, with a PDUFA target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:50.045Z",
     "filedAt": "2026-08-06",
     "form": "10-Q",
     "cik": "0001704292"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1798749/000119312526459293/ck0001798749-20260930.htm",
     "accession": "0001193125-26-459293",
     "quote": "The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026.",
     "fetchedAt": "2026-11-14T11:20:57.133Z",
     "filedAt": "2026-11-13",
     "form": "10-Q",
     "cik": "0001798749"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1798749/000119312526341242/ck0001798749-20260630.htm",
     "accession": "0001193125-26-341242",
     "quote": "The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026.",
     "fetchedAt": "2026-11-12T05:57:43.915Z",
     "filedAt": "2026-08-10",
     "form": "10-Q",
     "cik": "0001798749"
    }
   ],
   "firstSeen": "2026-08-03",
   "lastSeen": "2026-11-13",
   "confidence": 0.96,
   "mentionedBy": [
    "0001704292",
    "0001798749"
   ],
   "indication": "immunoglobulin A nephropathy",
   "pageUrl": "https://sec-api.dev/pdufa/povetacicept"
  },
  {
   "id": "nct05339126-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-30",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "companyCik": "0001528287",
   "ticker": "NPCE",
   "indication": "Epilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable",
   "phase": "2",
   "sponsorName": "NeuroPace",
   "title": "RNS System LGS Feasibility Study",
   "nctId": "NCT05339126",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05339126",
     "quote": "NCT05339126 (RNS System LGS Feasibility Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor NeuroPace.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/companies/npce/catalysts"
  },
  {
   "id": "nct05438407-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-30",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "leniolisib",
   "companyCik": "0001828316",
   "ticker": "PHAR",
   "indication": "APDS",
   "phase": "3",
   "sponsorName": "Pharming Technologies B.V.",
   "title": "Pediatric Patients Aged 4 to 11 Years With APDS",
   "nctId": "NCT05438407",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05438407",
     "quote": "NCT05438407 (Pediatric Patients Aged 4 to 11 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Pharming Technologies B.V..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/leniolisib"
  },
  {
   "id": "nct06643884-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-30",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "au-011",
   "companyCik": "0001501796",
   "ticker": "AURA",
   "indication": "Eye Cancer; Primary Cancer",
   "phase": "2",
   "sponsorName": "Aura Biosciences",
   "title": "Suprachoroidal Administration in Subjects With Metastases to the Choroid",
   "nctId": "NCT06643884",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06643884",
     "quote": "NCT06643884 (Suprachoroidal Administration in Subjects With Metastases to the Choroid): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Aura Biosciences.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/au-011"
  },
  {
   "id": "nct06812078-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-30",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "tak-360",
   "companyCik": "0001395064",
   "ticker": "TAK",
   "indication": "Idiopathic Hypersomnia",
   "phase": "2",
   "sponsorName": "Takeda",
   "title": "A Study of TAK-360 in Adults With Idiopathic Hypersomnia",
   "nctId": "NCT06812078",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06812078",
     "quote": "NCT06812078 (A Study of TAK-360 in Adults With Idiopathic Hypersomnia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/tak-360"
  },
  {
   "id": "nct06952699-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-30",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "tak-360",
   "companyCik": "0001395064",
   "ticker": "TAK",
   "indication": "Narcolepsy Type 2",
   "phase": "2",
   "sponsorName": "Takeda",
   "title": "A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)",
   "nctId": "NCT06952699",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06952699",
     "quote": "NCT06952699 (A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/tak-360"
  },
  {
   "id": "nct07081633-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-30",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "durvalumab",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "Hepatocellular Carcinoma",
   "phase": "2",
   "sponsorName": "AstraZeneca",
   "title": "TREMENDOUS-2: Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma",
   "nctId": "NCT07081633",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07081633",
     "quote": "NCT07081633 (Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor AstraZeneca.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/durvalumab"
  },
  {
   "id": "nct07365904-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-30",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "mr-130a-01-contraceptive-transdermal-patch-containing-norelgestromin-ngmn",
   "companyCik": "0001792044",
   "ticker": "VTRS",
   "indication": "Contraception",
   "phase": "2",
   "sponsorName": "Mylan Pharmaceuticals Inc",
   "title": "Investigating Ovulation Inhibition for Use as a Contraceptive",
   "nctId": "NCT07365904",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07365904",
     "quote": "NCT07365904 (Investigating Ovulation Inhibition for Use as a Contraceptive): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Mylan Pharmaceuticals Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:48:32.313Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/mr-130a-01-contraceptive-transdermal-patch-containing-norelgestromin-ngmn"
  },
  {
   "id": "nct07656727-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-11-30",
   "window": {
    "start": "2026-11-01",
    "end": "2026-11-30",
    "label": "November 2026"
   },
   "dateConfidence": "month",
   "drugId": "oral-bge-102",
   "companyCik": "0001709941",
   "ticker": "BIOA",
   "indication": "Obesity and Cardiovascular Risk",
   "phase": "2",
   "sponsorName": "BioAge Labs, Inc.",
   "title": "QUELL-CV: A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors",
   "nctId": "NCT07656727",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07656727",
     "quote": "NCT07656727 (A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor BioAge Labs, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/oral-bge-102"
  },
  {
   "id": "08b1080faf9eb3ea",
   "type": "pdufa",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "abatacept",
   "companyCik": "0001135951",
   "ticker": "RDY",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1135951/000157587226000536/rdy0931_ex99-1.htm",
     "accession": "0001575872-26-000536",
     "quote": "As we speak today, the goal date for abatacept is in mid-December 2026.",
     "fetchedAt": "2026-11-12T05:57:56.438Z",
     "filedAt": "2026-07-29",
     "form": "6-K"
    }
   ],
   "firstSeen": "2026-07-29",
   "lastSeen": "2026-07-29",
   "confidence": 0.83,
   "pageUrl": "https://sec-api.dev/pdufa/abatacept"
  },
  {
   "id": "0acafc522806b707",
   "type": "trial_start",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "rezpegaldesleukin",
   "companyCik": "0000906709",
   "ticker": "NKTR",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/906709/000119312526458868/nktr-20260930.htm",
     "accession": "0001193125-26-458868",
     "quote": "We intend to initiate a global registrational trial (ZENITH AA-1) in December 2026 to evaluate rezpegaldesleukin in patients who are 12 years of age or older with severe-to-very-severe alopecia areata.",
     "fetchedAt": "2026-11-14T11:21:01.801Z",
     "filedAt": "2026-11-13",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/906709/000119312526458868/nktr-20260930.htm",
     "accession": "0001193125-26-458868",
     "quote": "We intend to initiate a global registrational trial (ZENITH AA-1) in December 2026 to evaluate rezpegaldesleukin in patients who are 12 years of age or older with severe-to-very-severe",
     "fetchedAt": "2026-11-14T11:21:01.801Z",
     "filedAt": "2026-11-13",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/906709/000119312526349805/nktr-20260630.htm",
     "accession": "0001193125-26-349805",
     "quote": "We intend to initiate a global registrational trial (ZENITH-AA-1) in early 2027 to evaluate rezpegaldesleukin in patients who are 12 years of age or older with severe-to-very-severe alopecia areata.",
     "fetchedAt": "2026-11-12T05:57:35.437Z",
     "filedAt": "2026-08-14",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-08-14",
   "lastSeen": "2026-11-13",
   "confidence": 0.7,
   "pageUrl": "https://sec-api.dev/pdufa/rezpegaldesleukin"
  },
  {
   "id": "251c0437b2835055",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "companyCik": "0001326205",
   "ticker": "IGC",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1326205/000118518526005237/igc10q093026.htm",
     "accession": "0001185185-26-005237",
     "quote": "Company anticipates reporting topline results during the December 2026/January 2027 timeframe, subject to clinical trial and data management uncertainties.",
     "fetchedAt": "2026-11-12T05:57:10.959Z",
     "filedAt": "2026-11-06",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-11-06",
   "lastSeen": "2026-11-06",
   "confidence": 0.68,
   "pageUrl": "https://sec-api.dev/companies/igc/catalysts"
  },
  {
   "id": "333a70e64e233028",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "annamycin",
   "companyCik": "0001659617",
   "ticker": "MBRX",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/ex_1004839.htm",
     "accession": "0001437749-26-027835",
     "quote": "- MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout in December 2026 to February 2027 timeframe",
     "fetchedAt": "2026-11-12T05:57:35.342Z",
     "filedAt": "2026-08-14",
     "form": "8-K"
    }
   ],
   "firstSeen": "2026-08-14",
   "lastSeen": "2026-08-14",
   "confidence": 0.71,
   "supersededBy": "bf5da5375506abbc",
   "pageUrl": "https://sec-api.dev/pdufa/annamycin"
  },
  {
   "id": "37a98fcdd8709792",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "ersodetug",
   "companyCik": "0001509261",
   "ticker": "RZLT",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm",
     "accession": "0001104659-26-120205",
     "quote": "Topline results expected mid - December 2026",
     "fetchedAt": "2026-11-12T05:57:21.281Z",
     "filedAt": "2026-10-29",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465926115874/tm2627620d1_ex99-1.htm",
     "accession": "0001104659-26-115874",
     "quote": "Topline results expected mid-December 2026",
     "fetchedAt": "2026-11-12T05:57:24.091Z",
     "filedAt": "2026-10-14",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465926126502/tm2627558d10_ex99-1.htm",
     "accession": "0001104659-26-126502",
     "quote": "Topline results for the completed study, along with additional study details including statistical analysis of the primary endpoint, are expected by mid-December 2026",
     "fetchedAt": "2026-11-14T11:21:39.213Z",
     "filedAt": "2026-11-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465926123336/tm2628931d2_ex99-1.htm",
     "accession": "0001104659-26-123336",
     "quote": "Enrollment is complete and topline results are expected by mid-December 2026.",
     "fetchedAt": "2026-11-12T05:57:14.054Z",
     "filedAt": "2026-11-05",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-1.htm",
     "accession": "0001104659-26-001556",
     "quote": "Topline results are anticipated in the second half of 2026.",
     "fetchedAt": "2026-11-12T05:59:35.442Z",
     "filedAt": "2026-01-07",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm",
     "accession": "0001104659-26-001556",
     "quote": "Topline results expected second half of 2026 ICT: islet - cell tumor.",
     "fetchedAt": "2026-11-12T05:59:35.442Z",
     "filedAt": "2026-01-07",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm",
     "accession": "0001104659-25-109559",
     "quote": "Topline results expected second half of 2026 21 © 2025 Rezolute, Inc. Proprietary and Confidential.",
     "fetchedAt": "2026-11-12T05:59:50.056Z",
     "filedAt": "2025-11-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465925047832/tm2514822d1_ex99-1.htm",
     "accession": "0001104659-25-047832",
     "quote": "study, is anticipated to begin in the middle of 2025 with topline data expected in the second half of 2026.",
     "fetchedAt": "2026-11-12T06:00:49.743Z",
     "filedAt": "2025-05-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465925012173/tm255593d1_ex99-1.htm",
     "accession": "0001104659-25-012173",
     "quote": "Topline results are expected in the second half of 2026.",
     "fetchedAt": "2026-11-12T06:01:56.089Z",
     "filedAt": "2025-02-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465925001666/tm252102d1_ex99-1.htm",
     "accession": "0001104659-25-001666",
     "quote": "§ Study start expected in the first half of 2025 and topline results expected in the second half of 2026.",
     "fetchedAt": "2026-11-12T06:02:02.164Z",
     "filedAt": "2025-01-07",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/tm2625842d1_ex99-1.htm",
     "accession": "0001104659-26-110412",
     "quote": "Enrollment is in progress and topline results are expected before the end of 2026.",
     "fetchedAt": "2026-11-12T05:57:27.830Z",
     "filedAt": "2026-09-24",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/tm2614169d1_ex99-1.htm",
     "accession": "0001104659-26-059392",
     "quote": "Enrollment is in progress and topline results are expected in the second half of 2026.",
     "fetchedAt": "2026-11-12T05:58:17.699Z",
     "filedAt": "2026-05-12",
     "form": "8-K"
    }
   ],
   "firstSeen": "2025-01-07",
   "lastSeen": "2026-11-13",
   "confidence": 0.91,
   "indication": "hypoglycemia caused",
   "phase": "3",
   "pageUrl": "https://sec-api.dev/pdufa/ersodetug"
  },
  {
   "id": "51bf7581c991bc93",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "azetukalner",
   "companyCik": "0001582313",
   "ticker": "XENE",
   "phase": "3",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1582313/000119312526453521/xene-ex99_1.htm",
     "accession": "0001193125-26-453521",
     "quote": "Enrollment in Phase 3 X-NOVA2 study of azetukalner in MDD completed with topline data readout now expected in December 2026",
     "fetchedAt": "2026-11-12T05:57:10.380Z",
     "filedAt": "2026-11-09",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1582313/000119312526453521/xene-ex99_1.htm",
     "accession": "0001193125-26-453521",
     "quote": "\"Following the completion of enrollment in X-NOVA2, we are working toward our first Phase 3 data readout in psychiatry with topline results now expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:10.380Z",
     "filedAt": "2026-11-09",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1582313/000119312526453521/xene-ex99_1.htm",
     "accession": "0001193125-26-453521",
     "quote": "Xenon completed enrollment in the Phase 3 X-NOVA2 study in MDD with approximately 360 total patients; the topline data readout is now expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:10.380Z",
     "filedAt": "2026-11-09",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1582313/000119312526453701/xene-20260930.htm",
     "accession": "0001193125-26-453701",
     "quote": "We completed enrollment in the Phase 3 X-NOVA2 study in MDD with approximately 360 total patients; the topline data readout is now expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:10.314Z",
     "filedAt": "2026-11-09",
     "form": "10-Q"
    },
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06775379",
     "quote": "NCT06775379 (A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Xenon Pharmaceuticals Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-09",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "confidence": 0.76,
   "indication": "Major Depressive Disorder",
   "nctId": "NCT06775379",
   "title": "X-NOVA2: A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder",
   "sponsorName": "Xenon Pharmaceuticals Inc.",
   "pageUrl": "https://sec-api.dev/pdufa/azetukalner"
  },
  {
   "id": "5f94ca86d0000d95",
   "type": "readout_interim",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "zanubrutinib",
   "companyCik": "0001108205",
   "ticker": "CRIS",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1108205/000110465926127041/tm2629651d1_ex99-1.htm",
     "accession": "0001104659-26-127041",
     "quote": "To date, 12 patients have been enrolled in the study with initial data expected in December 2026.",
     "fetchedAt": "2026-11-14T11:21:23.336Z",
     "filedAt": "2026-11-13",
     "form": "8-K"
    }
   ],
   "firstSeen": "2026-11-13",
   "lastSeen": "2026-11-13",
   "confidence": 0.73,
   "pageUrl": "https://sec-api.dev/pdufa/zanubrutinib"
  },
  {
   "id": "637c17ebeefaf976",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "tabirafusp",
   "companyCik": "0001468748",
   "ticker": "KOD",
   "indication": "macular edema secondary to inflammation",
   "phase": "3",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/d185059dex991.htm",
     "accession": "0001193125-26-403481",
     "quote": "These forward-looking statements are not based on historical fact and include statements regarding: the planned multi-indication BLA submission for Zenkuda in the fourth quarter of 2026; the planned BLA submission for KS-101 in the second quarter of 2027; acceleration of the tabirafusp development program and the status of enrollment in, and expectations regarding the ALTO study; planned post-hoc analyses to identify patients that can benefit from IL-6 inhibition; and expectations regarding the announcement of topline data December 2026 for KSI-101 in the Phase 3 PEAK study in patients with macular edema secondary to inflammation (MESI).",
     "fetchedAt": "2026-11-12T05:57:26.879Z",
     "filedAt": "2026-09-28",
     "form": "8-K"
    }
   ],
   "firstSeen": "2026-09-28",
   "lastSeen": "2026-09-28",
   "confidence": 0.76,
   "pageUrl": "https://sec-api.dev/pdufa/tabirafusp"
  },
  {
   "id": "7399f2f93f78d8fe",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "ksi-101",
   "companyCik": "0001468748",
   "ticker": "KOD",
   "phase": "3",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526458248/kod-ex99_1.htm",
     "accession": "0001193125-26-458248",
     "quote": "Phase 3 PEAK Study (KSI-101) - Pivotal Analysis 1 Topline Data Expected December 2026",
     "fetchedAt": "2026-11-13T23:21:02.154Z",
     "filedAt": "2026-11-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/d185059dex991.htm",
     "accession": "0001193125-26-403481",
     "quote": "Our third late-stage asset, KSI-101, is being developed for macular edema secondary to inflammation, or MESI, with our first topline readout from its Phase 3 program expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:26.879Z",
     "filedAt": "2026-09-28",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526211811/kod-ex99_1.htm",
     "accession": "0001193125-26-211811",
     "quote": "KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI), with topline data readouts expected to begin in 4Q 2026.",
     "fetchedAt": "2026-11-12T05:58:23.227Z",
     "filedAt": "2026-05-07",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/kod-ex99_1.htm",
     "accession": "0001193125-26-134854",
     "quote": "KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI), with topline data readouts expected to begin in 4Q 2026.",
     "fetchedAt": "2026-11-12T05:58:40.370Z",
     "filedAt": "2026-03-31",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312525280125/kod-ex99_1.htm",
     "accession": "0001193125-25-280125",
     "quote": "KSI-101 is a bispecific protein being explored in two Phase 3 studies in Macular Edema Secondary to Inflammation (MESI), with topline data readouts expected in 4Q 2026 (PEAK) and 1Q 2027 (PINNACLE).",
     "fetchedAt": "2026-11-12T05:59:45.807Z",
     "filedAt": "2025-11-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000095017025107982/kod-ex99_1.htm",
     "accession": "0000950170-25-107982",
     "quote": "KSI-101 - Phase 3 topline data expected in 4Q 2026 - 1Q2027 (18 months)",
     "fetchedAt": "2026-11-12T06:00:18.851Z",
     "filedAt": "2025-08-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526458248/kod-ex99_1.htm",
     "accession": "0001193125-26-458248",
     "quote": "Enrollment of the first 300-patient cohort in the PEAK trial supporting Pivotal Analysis 1 has completed and topline results remain on track for a December 2026 release.",
     "fetchedAt": "2026-11-13T23:21:02.154Z",
     "filedAt": "2026-11-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526458248/kod-ex99_1.htm",
     "accession": "0001193125-26-458248",
     "quote": "Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.",
     "fetchedAt": "2026-11-13T23:21:02.154Z",
     "filedAt": "2026-11-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-ex99_1.htm",
     "accession": "0001193125-26-349107",
     "quote": "Topline data from Pivotal Analysis 1 are expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:38.123Z",
     "filedAt": "2026-08-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-ex99_1.htm",
     "accession": "0001193125-26-349107",
     "quote": "Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.",
     "fetchedAt": "2026-11-12T05:57:38.123Z",
     "filedAt": "2026-08-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526127041/d283186dex991.htm",
     "accession": "0001193125-26-127041",
     "quote": "Leaning into FDA's new single-pivotal-trial default option for approval, we are also anticipating a potential BLA submission for KSI-501 in wet AMD after the DAYBREAK study primary endpoint readout (expected 3Q2026, if successful) and for KSI-101 in Macular Edema Secondary to Inflammation (MESI) after the PEAK study pivotal analysis 1 readout (expected 4Q2026, if successful).\"",
     "fetchedAt": "2026-11-12T05:58:46.120Z",
     "filedAt": "2026-03-27",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526458399/kod-20260930.htm",
     "accession": "0001193125-26-458399",
     "quote": "Enrollment of the first 300-patient cohort in the PEAK trial supporting Pivotal Analysis 1 has completed and topline results remain on track for a December 2026 release.",
     "fetchedAt": "2026-11-13T11:21:06.024Z",
     "filedAt": "2026-11-12",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2025-08-13",
   "lastSeen": "2026-11-12",
   "confidence": 0.91,
   "pageUrl": "https://sec-api.dev/pdufa/ksi-101"
  },
  {
   "id": "74c838295ce4dfdf",
   "type": "nda_bla_submission",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "indegene",
   "companyCik": "0001862150",
   "ticker": "CING",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm",
     "accession": "0001493152-26-051841",
     "quote": "Company expects to resubmit the new drug application (NDA) for CTx-1301 between December 2026 and January 2027.",
     "fetchedAt": "2026-11-13T23:21:45.659Z",
     "filedAt": "2026-11-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm",
     "accession": "0001493152-26-051841",
     "quote": "As announced on November 9, 2026, the Company expects to resubmit the NDA between December 2026 and January 2027.",
     "fetchedAt": "2026-11-13T23:21:45.659Z",
     "filedAt": "2026-11-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm",
     "accession": "0001493152-26-051841",
     "quote": "FDA issued a Complete Response Letter for the CTx-1301 NDA; the Company and its CDMO have since substantially completed the manufacturing work required to address the CMC requests, and the Company expects to resubmit the NDA between December 2026 and January 2026.",
     "fetchedAt": "2026-11-13T23:21:45.659Z",
     "filedAt": "2026-11-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm",
     "accession": "0001493152-26-051841",
     "quote": "\"With the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301, and we expect to do so by January 2027, potentially sooner,\" stated Cingulate Chairman and CEO Shane J. Schaffer.",
     "fetchedAt": "2026-11-13T23:21:45.659Z",
     "filedAt": "2026-11-13",
     "form": "8-K"
    }
   ],
   "firstSeen": "2026-11-13",
   "lastSeen": "2026-11-13",
   "confidence": 0.64,
   "pageUrl": "https://sec-api.dev/pdufa/indegene"
  },
  {
   "id": "82167d4e681e9ad5",
   "type": "readout_interim",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "ep-104",
   "companyCik": "0001581178",
   "ticker": "EPRX",
   "phase": "2",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm",
     "accession": "0001193125-26-455405",
     "quote": "In December 2026, the Company expects to release interim data from the Phase 2b portion of the RESOLVE study.",
     "fetchedAt": "2026-11-12T05:57:07.073Z",
     "filedAt": "2026-11-10",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm",
     "accession": "0001193125-26-455405",
     "quote": "Interim data from the Phase 2b portion of the RESOLVE study is expected to be available in December 2026.",
     "fetchedAt": "2026-11-12T05:57:07.073Z",
     "filedAt": "2026-11-10",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000119312526345045/d153391dex992.htm",
     "accession": "0001193125-26-345045",
     "quote": "In Q4 2026, the Company expects to release interim data from the Phase 2b portion of the",
     "fetchedAt": "2026-11-12T05:57:42.340Z",
     "filedAt": "2026-08-11",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000119312526219802/d133809dex992.htm",
     "accession": "0001193125-26-219802",
     "quote": "In Q4 2026, the Company expects to release interim data from the Phase 2b portion of the",
     "fetchedAt": "2026-11-12T05:58:16.110Z",
     "filedAt": "2026-05-12",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000119312526219802/d133809dex992.htm",
     "accession": "0001193125-26-219802",
     "quote": "Interim data from the Phase 2b portion of the RESOLVE study is expected to be available in Q4 2026.",
     "fetchedAt": "2026-11-12T05:58:16.110Z",
     "filedAt": "2026-05-12",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000117184326007331/exh_991.htm",
     "accession": "0001171843-26-007331",
     "quote": "Phase 2b interim analysis expected in December 2026",
     "fetchedAt": "2026-11-12T05:57:07.076Z",
     "filedAt": "2026-11-10",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000117184326007331/exh_991.htm",
     "accession": "0001171843-26-007331",
     "quote": "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:07.076Z",
     "filedAt": "2026-11-10",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex993.htm",
     "accession": "0001193125-26-455405",
     "quote": "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:07.073Z",
     "filedAt": "2026-11-10",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000117184326006648/exh_991.htm",
     "accession": "0001171843-26-006648",
     "quote": "Interim analysis of the Phase 2b portion of the study is on track for December 2026",
     "fetchedAt": "2026-11-12T05:57:23.785Z",
     "filedAt": "2026-10-15",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000117184326006648/exh_991.htm",
     "accession": "0001171843-26-006648",
     "quote": "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:23.785Z",
     "filedAt": "2026-10-15",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000117184326006551/exh_991.htm",
     "accession": "0001171843-26-006551",
     "quote": "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:24.686Z",
     "filedAt": "2026-10-09",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1581178/000117184326006307/exh_991.htm",
     "accession": "0001171843-26-006307",
     "quote": "The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:26.206Z",
     "filedAt": "2026-09-30",
     "form": "6-K"
    }
   ],
   "firstSeen": "2026-05-12",
   "lastSeen": "2026-11-10",
   "confidence": 0.71,
   "pageUrl": "https://sec-api.dev/pdufa/ep-104"
  },
  {
   "id": "8641054daf399975",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "claseprubart",
   "companyCik": "0001690585",
   "ticker": "DNTH",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-ex99_1.htm",
     "accession": "0001690585-26-000029",
     "quote": "2 MoMeNtum Top-line Data Anticipated Q4'26 Q4'26",
     "fetchedAt": "2026-11-12T05:58:03.828Z",
     "filedAt": "2026-06-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_2.htm",
     "accession": "0001193125-26-097555",
     "quote": "Provide CAPTIVATE Part B top-line guidance by the end of 2026.",
     "fetchedAt": "2026-11-12T05:59:05.521Z",
     "filedAt": "2026-03-09",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm",
     "accession": "0001690585-26-000040",
     "quote": "In August 2026, we announced the completion of enrollment of the MoMeNtum trial, which exceeded its enrollment target of 36 patients, and top-line results with 46 patients are expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:15.184Z",
     "filedAt": "2026-11-04",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000169058526000034/dnth-20260630.htm",
     "accession": "0001690585-26-000034",
     "quote": "In August 2026, we announced the completion of enrollment of the MoMeNtum trial, which exceeded its enrollment target of 36 patients, and top-line results with 46 patients are expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:52.988Z",
     "filedAt": "2026-08-04",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000169058526000034/dnth-20260630.htm",
     "accession": "0001690585-26-000034",
     "quote": "We expect to provide CAPTIVATE Part B top-line guidance by the end of 2026.",
     "fetchedAt": "2026-11-12T05:57:52.988Z",
     "filedAt": "2026-08-04",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000169058526000022/dnth-20260331.htm",
     "accession": "0001690585-26-000022",
     "quote": "We expect to provide CAPTIVATE Part B top-line guidance by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:26.813Z",
     "filedAt": "2026-05-05",
     "form": "10-Q"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm",
     "accession": "0001690585-26-000021",
     "quote": "Dianthus is building a neuromuscular franchise with claseprubart and expects to initiate a Phase 3 trial in generalized Myasthenia Gravis in mid-2026, with top-line results expected in 2H'28, report top-line data from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in Q4'26, and provide an update on timing of top-line data from Part B of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy by YE'26.",
     "fetchedAt": "2026-11-12T05:58:26.815Z",
     "filedAt": "2026-05-05",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm",
     "accession": "0001690585-26-000021",
     "quote": "Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for Q4'26",
     "fetchedAt": "2026-11-12T05:58:26.815Z",
     "filedAt": "2026-05-05",
     "form": "8-K"
    },
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06537999",
     "quote": "NCT06537999 (A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Dianthus Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm",
     "accession": "0001690585-26-000021",
     "quote": "Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) on track to initiate in mid-2026; top-line results anticipated in 2H'28",
     "fetchedAt": "2026-11-12T05:58:26.815Z",
     "filedAt": "2026-05-05",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-ex99_1.htm",
     "accession": "0001690585-26-000021",
     "quote": "Phase 3 EMERGE trial on track to initiate in mid-2026, with top-line results expected in 2H'28: Following the successful completion of our end-of-Phase 2 meeting with the FDA in the first quarter of 2026, a Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W S.C. and 300mg/2mL Q4W S.C. in gMG patients is on track to initiate in mid-2026, with top-line results expected in 2H'28.",
     "fetchedAt": "2026-11-12T05:58:26.815Z",
     "filedAt": "2026-05-05",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_1.htm",
     "accession": "0001193125-26-097555",
     "quote": "Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) expected to initiate in mid-2026; top-line results anticipated in 2H'28",
     "fetchedAt": "2026-11-12T05:59:05.521Z",
     "filedAt": "2026-03-09",
     "form": "8-K"
    }
   ],
   "firstSeen": "2026-03-09",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "confidence": 0.87,
   "phase": "3",
   "indication": "Multifocal Motor Neuropathy",
   "nctId": "NCT06537999",
   "title": "MOMENTUM: A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy",
   "sponsorName": "Dianthus Therapeutics",
   "pageUrl": "https://sec-api.dev/pdufa/claseprubart"
  },
  {
   "id": "a08b5f9f96fd2eb8",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "empasiprubart",
   "companyCik": "0001697862",
   "ticker": "ARGX",
   "phase": "3",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm",
     "accession": "0001697862-26-000034",
     "quote": "•Topline results from the Phase 3 EMPASSION study (MMN) expected in December 2026",
     "fetchedAt": "2026-11-12T05:57:22.926Z",
     "filedAt": "2026-10-22",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/a04earningspressreleasehy.htm",
     "accession": "0001697862-25-000042",
     "quote": "•Topline results from registrational EMPASSION study (MMN) evaluating empasiprubart head-to-head versus IVIg expected in second half of 2026",
     "fetchedAt": "2026-11-12T06:00:32.772Z",
     "filedAt": "2025-07-31",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm",
     "accession": "0001697862-25-000028",
     "quote": "•Topline results from registrational EMPASSION study (MMN) evaluating empasiprubart head-to-head versus IVIg expected in second half of 2026",
     "fetchedAt": "2026-11-12T06:00:53.413Z",
     "filedAt": "2025-05-08",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786225000028/a02earningspressreleaseq1.htm",
     "accession": "0001697862-25-000028",
     "quote": "(7) its plans to develop empasiprubart, including (a) registrational EMPASSION study in MMN, with topline results expected in second half of 2026, (b) registrational EMVIGORATE study in CIDP, expected to start in first half of 2025 and (c) topline results for DGM and DM expected in second half of 2025 and first half of 2026, respectively",
     "fetchedAt": "2026-11-12T06:00:53.413Z",
     "filedAt": "2025-05-08",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm",
     "accession": "0001697862-25-000006",
     "quote": "•Registrational EMPASSION study ongoing in MMN evaluating empasiprubart head-to-head versus IVIg; topline results expected in second half of 2026",
     "fetchedAt": "2026-11-12T06:01:43.998Z",
     "filedAt": "2025-02-27",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786225000006/a09earningspressreleaseq42.htm",
     "accession": "0001697862-25-000006",
     "quote": "its plans to develop empasiprubart, including: (1) registrational EMPASSION study in MMN, with topline results expected in second half of 2026",
     "fetchedAt": "2026-11-12T06:01:43.998Z",
     "filedAt": "2025-02-27",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000110465925002791/tm253121d1_ex99-1.htm",
     "accession": "0001104659-25-002791",
     "quote": "Registrational EMPASSION study ongoing in MMN evaluating empasiprubart head-to-head versus IVIg; topline results expected in second half of 2026",
     "fetchedAt": "2026-11-12T06:02:01.097Z",
     "filedAt": "2025-01-13",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786226000033/a04earningspressreleasehy.htm",
     "accession": "0001697862-26-000033",
     "quote": "Registrational MMN study readout for empasiprubart on track for 4Q26, supporting a second pipeline-in-a-product opportunity",
     "fetchedAt": "2026-11-12T05:57:57.323Z",
     "filedAt": "2026-07-23",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786226000033/a04earningspressreleasehy.htm",
     "accession": "0001697862-26-000033",
     "quote": "•Topline results from registrational EMPASSION study (MMN) expected in fourth quarter of 2026",
     "fetchedAt": "2026-11-12T05:57:57.323Z",
     "filedAt": "2026-07-23",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786225000059/a02earningspressreleaseq3.htm",
     "accession": "0001697862-25-000059",
     "quote": "•Topline results from registrational EMPASSION study (MMN) expected in second half of 2026",
     "fetchedAt": "2026-11-12T06:00:02.412Z",
     "filedAt": "2025-10-30",
     "form": "6-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1697862/000169786225000042/argx-20250630_d2.htm",
     "accession": "0001697862-25-000042",
     "quote": "2027, respectively, (6) its plans to develop empasiprubart, including (a) registrational EMPASSION study in MMN, with topline results expected in second half of 2026, (b) registrational EMVIGORATE study in CIDP, expected to start in first half of 2025 and (c) topline results for DGM and DM expected in second half of 2025 and first half of 2026, respectively, (7) its plans to develop ARGX-119, including: (a) the registrational study to start in CMS in 2026; (b)",
     "fetchedAt": "2026-11-12T06:00:32.772Z",
     "filedAt": "2025-07-31",
     "form": "6-K"
    },
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06742190",
     "quote": "NCT06742190 (A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor argenx.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2025-01-13",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "confidence": 0.87,
   "indication": "Multifocal Motor Neuropathy (MMN); MMN",
   "nctId": "NCT06742190",
   "title": "Empassion: A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy",
   "sponsorName": "argenx",
   "pageUrl": "https://sec-api.dev/pdufa/empasiprubart"
  },
  {
   "id": "ad42b0e19992b06d",
   "type": "readout_interim",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "palazestrant",
   "companyCik": "0001750284",
   "ticker": "OLMA",
   "phase": "1/2",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm",
     "accession": "0001193125-26-454421",
     "quote": "The Phase 1b/2 study investigating palazestrant in combination with atirmociclib has completed enrollment and we expect to present initial data at the San Antonio Breast Cancer Symposium (SABCS) in December 2026.",
     "fetchedAt": "2026-11-12T05:57:07.737Z",
     "filedAt": "2026-11-10",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-11-10",
   "lastSeen": "2026-11-10",
   "confidence": 0.75,
   "pageUrl": "https://sec-api.dev/pdufa/palazestrant"
  },
  {
   "id": "b8445e0faf10cdc2",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "imu-838",
   "companyCik": "0001280776",
   "ticker": "IMUX",
   "indication": "relapsing multiple sclerosis",
   "phase": "3",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000149315226051543/ex99-1.htm",
     "accession": "0001493152-26-051543",
     "quote": "The company's lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026.",
     "fetchedAt": "2026-11-14T11:21:27.378Z",
     "filedAt": "2026-11-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526001071/e665684_ex99-1.htm",
     "accession": "0001193805-26-001071",
     "quote": "The company's lead development program, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials for the treatment of relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026.",
     "fetchedAt": "2026-11-12T05:57:42.439Z",
     "filedAt": "2026-08-11",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526000703/e665514_ex99-1.htm",
     "accession": "0001193805-26-000703",
     "quote": "The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:06.377Z",
     "filedAt": "2026-05-28",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/e665513_ex99-1.htm",
     "accession": "0001193805-26-000696",
     "quote": "The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:06.465Z",
     "filedAt": "2026-05-27",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/e665479_ex99-1.htm",
     "accession": "0001193805-26-000645",
     "quote": "The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:08.671Z",
     "filedAt": "2026-05-19",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/e665461_ex99-1.htm",
     "accession": "0001193805-26-000593",
     "quote": "The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:14.323Z",
     "filedAt": "2026-05-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/e665394_ex99-1.htm",
     "accession": "0001193805-26-000516",
     "quote": "The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:31.463Z",
     "filedAt": "2026-04-28",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526000495/e665386_ex99-1.htm",
     "accession": "0001193805-26-000495",
     "quote": "The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:32.552Z",
     "filedAt": "2026-04-23",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526000382/e665306_ex99-1.htm",
     "accession": "0001193805-26-000382",
     "quote": "The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:38.207Z",
     "filedAt": "2026-04-01",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526000370/e665296_ex99-1.htm",
     "accession": "0001193805-26-000370",
     "quote": "The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:40.174Z",
     "filedAt": "2026-03-31",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1280776/000119380526000181/e665186_ex99-1.htm",
     "accession": "0001193805-26-000181",
     "quote": "\"The phase 3 ENSURE-1 and ENSURE-2 trials of our lead asset, orally available nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS) continue to progress, with top-line data expected to be available by the end of 2026,\" stated Daniel Vitt, Ph.D.,",
     "fetchedAt": "2026-11-12T05:59:16.594Z",
     "filedAt": "2026-02-26",
     "form": "8-K"
    },
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05134441",
     "quote": "NCT05134441 (Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Immunic AG.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2025-05-28",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "confidence": 0.91,
   "nctId": "NCT05134441",
   "title": "ENSURE-1: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis",
   "sponsorName": "Immunic AG",
   "pageUrl": "https://sec-api.dev/pdufa/imu-838"
  },
  {
   "id": "b991a4dd7047c2bb",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "tedromer",
   "companyCik": "0001468748",
   "ticker": "KOD",
   "phase": "3",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-ex99_1.htm",
     "accession": "0001193125-26-349107",
     "quote": "Phase 3 PEAK Study - Pivotal Analysis 1 Topline Data Expected December 2026",
     "fetchedAt": "2026-11-12T05:57:38.123Z",
     "filedAt": "2026-08-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526127041/d283186dex991.htm",
     "accession": "0001193125-26-127041",
     "quote": "after the PEAK study pivotal analysis 1 readout (expected 4Q2026, if successful); and the possibility that KSI-501 may be a disease-modifying therapy for retinal vascular diseases based on preclinical data.",
     "fetchedAt": "2026-11-12T05:58:46.120Z",
     "filedAt": "2026-03-27",
     "form": "8-K"
    }
   ],
   "firstSeen": "2026-03-27",
   "lastSeen": "2026-08-13",
   "confidence": 0.81,
   "pageUrl": "https://sec-api.dev/pdufa/tedromer"
  },
  {
   "id": "e0fbf9f56e503702",
   "type": "readout_interim",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "companyCik": "0001730463",
   "ticker": "AUTL",
   "phase": "1",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1730463/000173046326000141/autlex-991pr111026.htm",
     "accession": "0001730463-26-000141",
     "quote": "AUTO8 in Light-Chain Amyloidosis The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at ASH in December 2026.",
     "fetchedAt": "2026-11-12T05:57:06.452Z",
     "filedAt": "2026-11-10",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1730463/000173046326000119/autlex-991pr110826a01.htm",
     "accession": "0001730463-26-000119",
     "quote": "AUTO8 in Light-Chain Amyloidosis The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at the end of 2026.",
     "fetchedAt": "2026-11-12T05:57:41.842Z",
     "filedAt": "2026-08-11",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/ex991autoluannualreporta.htm",
     "accession": "0001730463-26-000069",
     "quote": "We are advancing obe-cel into clinical development in progressive multiple sclerosis (\"MS\") and in October 2025, we have dosed our first patients in a Phase 1 dose escalation clinical trial, with initial data expected to be reported at the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:04.527Z",
     "filedAt": "2026-06-09",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/autlex-991pr140526.htm",
     "accession": "0001730463-26-000058",
     "quote": "AUTO8 in Light-Chain Amyloidosis The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:11.139Z",
     "filedAt": "2026-05-14",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1730463/000173046326000058/autlex-992cp140526.htm",
     "accession": "0001730463-26-000058",
     "quote": "Real world experience obe-cel data being generated by ROCCA Consortium in r/r aALL Developing and Delivering a New Generation of T Cell Therapies Phase 2 expansion enrolling; data expected at end of 2027 Aligned with FDA on protocol design to support potential registration Phase 2 enrolling; data expected in 2028 Aligned with FDA on protocol design to support potential registration Supported by external opportunities: Initial data reported; longer-term follow up expected at end of 2026 Phase 1 enrolling; initial data expected at end of 2026; full data in 2027",
     "fetchedAt": "2026-11-12T05:58:11.139Z",
     "filedAt": "2026-05-14",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1730463/000173046326000148/autl-20260930.htm",
     "accession": "0001730463-26-000148",
     "quote": "•The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at the American Society of Hematology meeting to held in December 2026.",
     "fetchedAt": "2026-11-12T05:57:06.418Z",
     "filedAt": "2026-11-10",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-05-14",
   "lastSeen": "2026-11-10",
   "confidence": 0.68,
   "pageUrl": "https://sec-api.dev/companies/autl/catalysts"
  },
  {
   "id": "e923e03c735df37b",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "companyCik": "0001468748",
   "ticker": "KOD",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526458248/kod-ex99_1.htm",
     "accession": "0001193125-26-458248",
     "quote": "We have completed enrollment of the first 300-patient pivotal cohort in the PEAK trial, supporting Pivotal Analysis 1, with topline clinical data from the 24-week primary endpoint on track for a December 2026 release.",
     "fetchedAt": "2026-11-13T23:21:02.154Z",
     "filedAt": "2026-11-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-ex99_1.htm",
     "accession": "0001193125-26-349107",
     "quote": "Topline data readouts for Pivotal Analysis 1 (PEAK patients 1 - 300) and Pivotal Analysis 2 (PEAK patients 301 - 600 and PINNACLE patients 1 - 300) are expected in December 2026 and 2Q 2027, respectively.",
     "fetchedAt": "2026-11-12T05:57:38.123Z",
     "filedAt": "2026-08-13",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526458399/kod-20260930.htm",
     "accession": "0001193125-26-458399",
     "quote": "We have completed enrollment of the first 300-patient pivotal cohort in the PEAK trial, supporting Pivotal Analysis 1, with topline clinical data from the 24-week primary endpoint on track for a December 2026 release.",
     "fetchedAt": "2026-11-13T11:21:06.024Z",
     "filedAt": "2026-11-12",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526349251/kod-20260630.htm",
     "accession": "0001193125-26-349251",
     "quote": "Enrollment of the first 300-patient cohort in the PEAK trial supporting Pivotal Analysis 1 has completed and topline results are expected in December 2026.",
     "fetchedAt": "2026-11-12T05:57:38.111Z",
     "filedAt": "2026-08-13",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1468748/000119312526349251/kod-20260630.htm",
     "accession": "0001193125-26-349251",
     "quote": "Topline data readouts for Pivotal Analysis 1 (PEAK patients 1 - 300) and Pivotal Analysis 2 (PEAK patients 301 - 600 and PINNACLE patients 1 - 300) are expected in December 2026 and 2Q 2027, respectively.",
     "fetchedAt": "2026-11-12T05:57:38.111Z",
     "filedAt": "2026-08-13",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-08-13",
   "lastSeen": "2026-11-12",
   "confidence": 0.76,
   "pageUrl": "https://sec-api.dev/companies/kod/catalysts"
  },
  {
   "id": "f7ddf87d916a0300",
   "type": "readout_topline",
   "dateConfidence": "month",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "Dec 2026"
   },
   "drugId": "litifilimab",
   "companyCik": "0000875045",
   "ticker": "BIIB",
   "phase": "3",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/exhibit991-q32026pressrele.htm",
     "accession": "0000875045-26-000094",
     "quote": "•The Company expects to announce top line data from both TOPAZ-1 and TOPAZ-2 Phase 3 studies, evaluating litifilimab in SLE, in the first half of December 2026.",
     "fetchedAt": "2026-11-12T05:57:21.566Z",
     "filedAt": "2026-10-28",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/exhibit991-q32025pressrele.htm",
     "accession": "0000875045-25-000047",
     "quote": "•Today announced both litifilimab Phase 3 studies for systemic lupus erythematosus fully enrolled with expected data readout for both studies now accelerated to H2 2026",
     "fetchedAt": "2026-11-12T06:00:02.573Z",
     "filedAt": "2025-10-30",
     "form": "8-K"
    },
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04895241",
     "quote": "NCT04895241 (A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor Biogen.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    },
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04961567",
     "quote": "NCT04961567 (A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-27 (ESTIMATED); Lead Sponsor Biogen.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    },
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05531565",
     "quote": "NCT05531565 (A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-10-20 (ESTIMATED); Lead Sponsor Biogen.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2025-10-30",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "confidence": 0.91,
   "indication": "Lupus Erythematosus, Systemic",
   "nctId": "NCT04895241",
   "title": "TOPAZ-1: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus",
   "sponsorName": "Biogen",
   "pageUrl": "https://sec-api.dev/pdufa/litifilimab"
  },
  {
   "id": "nct01804686-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "ibrutinib",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma",
   "phase": "3",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "CAN3001: A Long-term Extension Study of PCI-32765 (Ibrutinib)",
   "nctId": "NCT01804686",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT01804686",
     "quote": "NCT01804686 (A Long-term Extension Study of PCI-32765 (Ibrutinib)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/ibrutinib"
  },
  {
   "id": "nct02227251-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "selinexor",
   "companyCik": "0001503802",
   "ticker": "KPTIQ",
   "indication": "Diffuse Large B-cell Lymphoma",
   "phase": "2",
   "sponsorName": "Karyopharm Therapeutics Inc",
   "title": "Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
   "nctId": "NCT02227251",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT02227251",
     "quote": "NCT02227251 (Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/selinexor"
  },
  {
   "id": "nct02227251-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "selinexor",
   "companyCik": "0001503802",
   "ticker": "KPTIQ",
   "indication": "Diffuse Large B-cell Lymphoma",
   "phase": "2",
   "sponsorName": "Karyopharm Therapeutics Inc",
   "title": "Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",
   "nctId": "NCT02227251",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT02227251",
     "quote": "NCT02227251 (Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526047670/kpti-ex99_1.htm",
     "accession": "0001193125-26-047670",
     "quote": "In endometrial cancer, we remain on track to report top-line data in mid-2026 from our Phase 3 trial evaluating selinexor in a defined, biomarker-driven patient population with limited effective treatment options.",
     "fetchedAt": "2026-11-12T05:59:27.583Z",
     "filedAt": "2026-02-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/kpti-ex99_1.htm",
     "accession": "0001193125-26-347897",
     "quote": "Announce topline data from the event-driven Phase 3 XPORT-MM-031 (EMN29) trial expected in the second half of 2026.",
     "fetchedAt": "2026-11-12T05:57:38.172Z",
     "filedAt": "2026-08-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526222808/kpti-ex99_1.htm",
     "accession": "0001193125-26-222808",
     "quote": "Announce topline data from the event-driven, Phase 3 XPORT-MM-031 (EMN29) trial, expected in the second half of 2026.",
     "fetchedAt": "2026-11-12T05:58:12.003Z",
     "filedAt": "2026-05-14",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526047670/kpti-ex99_1.htm",
     "accession": "0001193125-26-047670",
     "quote": "Top-line data from the event-driven, Phase 3 XPORT-MM-031 (EMN29) trial is expected in the second half of 2026.",
     "fetchedAt": "2026-11-12T05:59:27.583Z",
     "filedAt": "2026-02-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/kpti-ex99_1.htm",
     "accession": "0001193125-26-009738",
     "quote": "- Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 -",
     "fetchedAt": "2026-11-12T05:59:33.861Z",
     "filedAt": "2026-01-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/kpti-ex99_1.htm",
     "accession": "0001193125-26-009738",
     "quote": "\"In endometrial cancer, we remain focused and on track to report top-line data from our Phase 3 XPORT-EC-042 trial in mid-2026, representing a significant opportunity to transform patient outcomes in a targeted, biomarker driven patient population.",
     "fetchedAt": "2026-11-12T05:59:33.861Z",
     "filedAt": "2026-01-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/kpti-ex99_1.htm",
     "accession": "0001193125-26-009738",
     "quote": "Top-line data from the event-driven, Phase 3 XPORT-EC-042 trial is expected in mid-2026.",
     "fetchedAt": "2026-11-12T05:59:33.861Z",
     "filedAt": "2026-01-12",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000095017025022764/kpti-ex99_1.htm",
     "accession": "0000950170-25-022764",
     "quote": "\"In endometrial cancer, today we announced our updated plans for our Phase 3 trial and intend to primarily focus on the TP53 wild-type pMMR population, which represents approximately 50% of all women with endometrial cancer, and expect to share top-line data in mid-2026.\"",
     "fetchedAt": "2026-11-12T06:01:52.315Z",
     "filedAt": "2025-02-19",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526444164/d141618dex991.htm",
     "accession": "0001193125-26-444164",
     "quote": "The Company is also evaluating selinexor as a monotherapy in the Phase 2 SENTRY-2 trial in myelofibrosis, with topline data from the 60 mg cohort expected to be reported at a medical congress in the second half of 2026.",
     "fetchedAt": "2026-11-12T05:57:18.573Z",
     "filedAt": "2026-11-03",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/kpti-ex99_1.htm",
     "accession": "0001193125-26-347897",
     "quote": "Topline data from the Phase 2 SENTRY-2 60 mg cohort expected in the second half of 2026.",
     "fetchedAt": "2026-11-12T05:57:38.172Z",
     "filedAt": "2026-08-13",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/kpti-ex99_1.htm",
     "accession": "0001193125-26-009738",
     "quote": "The Company expects to report top-line data from all patients in the 60 mg cohort of the Phase 2 SENTRY-2 trial with at least 24 weeks of follow-up in the second half of 2026.",
     "fetchedAt": "2026-11-12T05:59:33.861Z",
     "filedAt": "2026-01-12",
     "form": "8-K"
    }
   ],
   "firstSeen": "2025-02-19",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "confidence": 0.86,
   "pageUrl": "https://sec-api.dev/pdufa/selinexor"
  },
  {
   "id": "nct03441113-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "momelotinib",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Primary Myelofibrosis",
   "phase": "2",
   "sponsorName": "GlaxoSmithKline",
   "title": "Extended Access of Momelotinib in Adults With Myelofibrosis",
   "nctId": "NCT03441113",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT03441113",
     "quote": "NCT03441113 (Extended Access of Momelotinib in Adults With Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/momelotinib"
  },
  {
   "id": "nct03604198-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "relacorilant",
   "companyCik": "0001088856",
   "ticker": "CORT",
   "indication": "Cushing Syndrome",
   "phase": "2",
   "sponsorName": "Corcept Therapeutics",
   "title": "Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome",
   "nctId": "NCT03604198",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT03604198",
     "quote": "NCT03604198 (Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/relacorilant"
  },
  {
   "id": "nct03604198-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "relacorilant",
   "companyCik": "0001088856",
   "ticker": "CORT",
   "indication": "Cushing Syndrome",
   "phase": "2",
   "sponsorName": "Corcept Therapeutics",
   "title": "Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome",
   "nctId": "NCT03604198",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT03604198",
     "quote": "NCT03604198 (Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/relacorilant"
  },
  {
   "id": "nct03683186-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "ralinepag",
   "companyCik": "0001082554",
   "ticker": "UTHR",
   "indication": "PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension",
   "phase": "3",
   "sponsorName": "United Therapeutics",
   "title": "A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension",
   "nctId": "NCT03683186",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT03683186",
     "quote": "NCT03683186 (A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor United Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/ralinepag"
  },
  {
   "id": "nct03683186-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "ralinepag",
   "companyCik": "0001082554",
   "ticker": "UTHR",
   "indication": "PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension",
   "phase": "3",
   "sponsorName": "United Therapeutics",
   "title": "A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension",
   "nctId": "NCT03683186",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT03683186",
     "quote": "NCT03683186 (A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor United Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/ralinepag"
  },
  {
   "id": "nct03767244-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-01",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "apalutamide",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Prostatic Neoplasms",
   "phase": "3",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "PROTEUS: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",
   "nctId": "NCT03767244",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT03767244",
     "quote": "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/apalutamide"
  },
  {
   "id": "nct03767244-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "apalutamide",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Prostatic Neoplasms",
   "phase": "3",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "PROTEUS: A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",
   "nctId": "NCT03767244",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT03767244",
     "quote": "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/apalutamide"
  },
  {
   "id": "nct04042844-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "brtx-100",
   "companyCik": "0001505497",
   "ticker": "BRTX",
   "indication": "Lumbar Disc Disease",
   "phase": "2",
   "sponsorName": "BioRestorative Therapies",
   "title": "A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)",
   "nctId": "NCT04042844",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04042844",
     "quote": "NCT04042844 (A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor BioRestorative Therapies.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/brtx-100"
  },
  {
   "id": "nct04042844-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "brtx-100",
   "companyCik": "0001505497",
   "ticker": "BRTX",
   "indication": "Lumbar Disc Disease",
   "phase": "2",
   "sponsorName": "BioRestorative Therapies",
   "title": "A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)",
   "nctId": "NCT04042844",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04042844",
     "quote": "NCT04042844 (A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor BioRestorative Therapies.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/brtx-100"
  },
  {
   "id": "nct04170283-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "zanubrutinib",
   "companyCik": "0001651308",
   "ticker": "ONC",
   "indication": "B-cell Malignancies",
   "phase": "3",
   "sponsorName": "BeOne Medicines",
   "title": "A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib",
   "nctId": "NCT04170283",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04170283",
     "quote": "NCT04170283 (A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor BeOne Medicines.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/zanubrutinib"
  },
  {
   "id": "nct04442022-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "selinexor-combination-therapy",
   "companyCik": "0001503802",
   "ticker": "KPTIQ",
   "indication": "Relapsed/Refractory Diffuse Large B-cell Lymphoma",
   "phase": "2/3",
   "sponsorName": "Karyopharm Therapeutics Inc",
   "title": "A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
   "nctId": "NCT04442022",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04442022",
     "quote": "NCT04442022 (A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/selinexor-combination-therapy"
  },
  {
   "id": "nct04442022-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "selinexor-combination-therapy",
   "companyCik": "0001503802",
   "ticker": "KPTIQ",
   "indication": "Relapsed/Refractory Diffuse Large B-cell Lymphoma",
   "phase": "2/3",
   "sponsorName": "Karyopharm Therapeutics Inc",
   "title": "A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma",
   "nctId": "NCT04442022",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04442022",
     "quote": "NCT04442022 (A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/selinexor-combination-therapy"
  },
  {
   "id": "nct04553133-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "pf-07104091-monotherapy",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer",
   "phase": "2",
   "sponsorName": "Pfizer",
   "title": "PF-07104091 as a Single Agent and in Combination Therapy",
   "nctId": "NCT04553133",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04553133",
     "quote": "NCT04553133 (PF-07104091 as a Single Agent and in Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/pf-07104091-monotherapy"
  },
  {
   "id": "nct04639986-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "sacituzumab-govitecan-hziy",
   "companyCik": "0000882095",
   "ticker": "GILD",
   "indication": "Metastatic Breast Cancer",
   "phase": "3",
   "sponsorName": "Gilead Sciences",
   "title": "Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)",
   "nctId": "NCT04639986",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04639986",
     "quote": "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy"
  },
  {
   "id": "nct04639986-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "sacituzumab-govitecan-hziy",
   "companyCik": "0000882095",
   "ticker": "GILD",
   "indication": "Metastatic Breast Cancer",
   "phase": "3",
   "sponsorName": "Gilead Sciences",
   "title": "Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)",
   "nctId": "NCT04639986",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04639986",
     "quote": "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy"
  },
  {
   "id": "nct04641247-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "niraparib",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Ovarian Neoplasms; Breast Neoplasms",
   "phase": "2",
   "sponsorName": "GlaxoSmithKline",
   "title": "A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study",
   "nctId": "NCT04641247",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04641247",
     "quote": "NCT04641247 (A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/niraparib"
  },
  {
   "id": "nct04658862-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "gemcitabine",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Urinary Bladder Neoplasms",
   "phase": "3",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "SunRISe-2: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder",
   "nctId": "NCT04658862",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04658862",
     "quote": "NCT04658862 (A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/gemcitabine"
  },
  {
   "id": "nct04704921-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "abbv-rgx-314",
   "companyCik": "0001551152",
   "ticker": "ABBV",
   "indication": "AMD; nAMD; Wet Age-related Macular Degeneration",
   "phase": "2/3",
   "sponsorName": "AbbVie",
   "title": "ATMOSPHERE: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD",
   "nctId": "NCT04704921",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04704921",
     "quote": "NCT04704921 (Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/abbv-rgx-314"
  },
  {
   "id": "nct04704921-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "abbv-rgx-314",
   "companyCik": "0001551152",
   "ticker": "ABBV",
   "indication": "AMD; nAMD; Wet Age-related Macular Degeneration",
   "phase": "2/3",
   "sponsorName": "AbbVie",
   "title": "ATMOSPHERE: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD",
   "nctId": "NCT04704921",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04704921",
     "quote": "NCT04704921 (Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/abbv-rgx-314"
  },
  {
   "id": "nct04879329-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "disitamab-vedotin",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Urothelial Carcinoma",
   "phase": "2",
   "sponsorName": "Seagen, a wholly owned subsidiary of Pfizer",
   "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2",
   "nctId": "NCT04879329",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04879329",
     "quote": "NCT04879329 (A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/disitamab-vedotin"
  },
  {
   "id": "nct04977024-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "covid-19-vaccine",
   "companyCik": "0000832489",
   "ticker": "GOVX",
   "indication": "COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia",
   "phase": "2",
   "sponsorName": "GeoVax, Inc.",
   "title": "SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer",
   "nctId": "NCT04977024",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04977024",
     "quote": "NCT04977024 (SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor GeoVax, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/covid-19-vaccine"
  },
  {
   "id": "nct05023018-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "neo100",
   "companyCik": "0001979414",
   "ticker": "NTHI",
   "indication": "Residual, Progressive or Recurrent Grade II or III Meningioma",
   "phase": "2",
   "sponsorName": "Neonc Technologies, Inc.",
   "title": "NEO100 and High-Grade Meningioma",
   "nctId": "NCT05023018",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05023018",
     "quote": "NCT05023018 (NEO100 and High-Grade Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Neonc Technologies, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    },
    {
     "kind": "sec_424b",
     "url": "https://www.sec.gov/Archives/edgar/data/1979414/000182912626009976/neonctechnologies_424b5.htm",
     "accession": "0001829126-26-009976",
     "quote": "Based on our current planning assumptions, we believe a Phase II data readout for NEO100 may be achievable by the end of 2026.",
     "fetchedAt": "2026-11-12T05:57:30.513Z",
     "filedAt": "2026-09-10",
     "form": "424B5"
    },
    {
     "kind": "sec_424b",
     "url": "https://www.sec.gov/Archives/edgar/data/1979414/000182912626006772/neonctechnologies_424b5.htm",
     "accession": "0001829126-26-006772",
     "quote": "Based on our current planning assumptions, we believe a Phase II data readout for NEO100 may be achievable by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:02.142Z",
     "filedAt": "2026-06-23",
     "form": "424B5"
    },
    {
     "kind": "sec_424b",
     "url": "https://www.sec.gov/Archives/edgar/data/1979414/000182912626003565/neonctechnologies_424b5.htm",
     "accession": "0001829126-26-003565",
     "quote": "Based on our current planning assumptions, we believe a Phase II data readout for NEO100 may be achievable by the end of 2026.",
     "fetchedAt": "2026-11-12T05:58:33.900Z",
     "filedAt": "2026-04-16",
     "form": "424B5"
    }
   ],
   "firstSeen": "2026-04-16",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "confidence": 0.7,
   "pageUrl": "https://sec-api.dev/pdufa/neo100"
  },
  {
   "id": "nct05059522-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "talazoparib",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Advanced Malignancies; NSCLC; Ovarian Cancer",
   "phase": "3",
   "sponsorName": "Pfizer",
   "title": "Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing",
   "nctId": "NCT05059522",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05059522",
     "quote": "NCT05059522 (Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/talazoparib"
  },
  {
   "id": "nct05065216-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "recombinant-human-tissue-kallikrein",
   "companyCik": "0001401040",
   "ticker": "DMAC",
   "indication": "Acute Stroke; Ischemic Stroke; Stroke",
   "phase": "2/3",
   "sponsorName": "DiaMedica Therapeutics Inc",
   "title": "ReMEDy2: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)",
   "nctId": "NCT05065216",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05065216",
     "quote": "NCT05065216 (Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor DiaMedica Therapeutics Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/recombinant-human-tissue-kallikrein"
  },
  {
   "id": "nct05065216-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "recombinant-human-tissue-kallikrein",
   "companyCik": "0001401040",
   "ticker": "DMAC",
   "indication": "Acute Stroke; Ischemic Stroke; Stroke",
   "phase": "2/3",
   "sponsorName": "DiaMedica Therapeutics Inc",
   "title": "ReMEDy2: Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)",
   "nctId": "NCT05065216",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05065216",
     "quote": "NCT05065216 (Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor DiaMedica Therapeutics Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/recombinant-human-tissue-kallikrein"
  },
  {
   "id": "nct05147467-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "apg2575",
   "companyCik": "0002023311",
   "ticker": "AAPG",
   "indication": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma",
   "phase": "2",
   "sponsorName": "Ascentage Pharma Group Inc.",
   "title": "Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL",
   "nctId": "NCT05147467",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05147467",
     "quote": "NCT05147467 (Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/apg2575"
  },
  {
   "id": "nct05147467-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "apg2575",
   "companyCik": "0002023311",
   "ticker": "AAPG",
   "indication": "Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma",
   "phase": "2",
   "sponsorName": "Ascentage Pharma Group Inc.",
   "title": "Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL",
   "nctId": "NCT05147467",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05147467",
     "quote": "NCT05147467 (Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/apg2575"
  },
  {
   "id": "nct05281471-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "olvimulogene-nanivacirepvec",
   "companyCik": "0001231457",
   "ticker": "GNLX",
   "phase": "3",
   "sponsorName": "Genelux Corporation",
   "title": "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",
   "nctId": "NCT05281471",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05281471",
     "quote": "NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Genelux Corporation.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/olvimulogene-nanivacirepvec"
  },
  {
   "id": "nct05281471-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "olvimulogene-nanivacirepvec",
   "companyCik": "0001231457",
   "ticker": "GNLX",
   "phase": "3",
   "sponsorName": "Genelux Corporation",
   "title": "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)",
   "nctId": "NCT05281471",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05281471",
     "quote": "NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Genelux Corporation.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/olvimulogene-nanivacirepvec"
  },
  {
   "id": "nct05303532-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "durvalumab",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "Cancer",
   "phase": "3",
   "sponsorName": "AstraZeneca",
   "title": "ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab",
   "nctId": "NCT05303532",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05303532",
     "quote": "NCT05303532 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor AstraZeneca.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/durvalumab"
  },
  {
   "id": "nct05327114-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "nipocalimab",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",
   "phase": "2/3",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
   "nctId": "NCT05327114",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05327114",
     "quote": "NCT05327114 (Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/nipocalimab"
  },
  {
   "id": "nct05392114-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "donidalorsen",
   "companyCik": "0000874015",
   "ticker": "IONS",
   "indication": "Hereditary Angioedema",
   "phase": "3",
   "sponsorName": "Ionis Pharmaceuticals, Inc.",
   "title": "A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)",
   "nctId": "NCT05392114",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05392114",
     "quote": "NCT05392114 (A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/donidalorsen"
  },
  {
   "id": "nct05392114-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "donidalorsen",
   "companyCik": "0000874015",
   "ticker": "IONS",
   "indication": "Hereditary Angioedema",
   "phase": "3",
   "sponsorName": "Ionis Pharmaceuticals, Inc.",
   "title": "A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)",
   "nctId": "NCT05392114",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05392114",
     "quote": "NCT05392114 (A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/donidalorsen"
  },
  {
   "id": "nct05396885-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "anitocabtagene-autoleucel",
   "companyCik": "0000882095",
   "ticker": "GILD",
   "indication": "Multiple Myeloma",
   "phase": "2",
   "sponsorName": "Kite, A Gilead Company",
   "title": "iMMagine-1: Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)",
   "nctId": "NCT05396885",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05396885",
     "quote": "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/anitocabtagene-autoleucel"
  },
  {
   "id": "nct05396885-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "anitocabtagene-autoleucel",
   "companyCik": "0000882095",
   "ticker": "GILD",
   "indication": "Multiple Myeloma",
   "phase": "2",
   "sponsorName": "Kite, A Gilead Company",
   "title": "iMMagine-1: Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)",
   "nctId": "NCT05396885",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05396885",
     "quote": "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/anitocabtagene-autoleucel"
  },
  {
   "id": "nct05456256-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "tavocept",
   "companyCik": "0001763950",
   "ticker": "LTRN",
   "indication": "Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung",
   "phase": "2",
   "sponsorName": "Lantern Pharma Inc.",
   "title": "HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma",
   "nctId": "NCT05456256",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05456256",
     "quote": "NCT05456256 (A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Lantern Pharma Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/tavocept"
  },
  {
   "id": "nct05456256-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "tavocept",
   "companyCik": "0001763950",
   "ticker": "LTRN",
   "indication": "Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung",
   "phase": "2",
   "sponsorName": "Lantern Pharma Inc.",
   "title": "HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma",
   "nctId": "NCT05456256",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05456256",
     "quote": "NCT05456256 (A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Lantern Pharma Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/tavocept"
  },
  {
   "id": "nct05464784-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "mn-001",
   "companyCik": "0001226616",
   "ticker": "MNOV",
   "indication": "Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease",
   "phase": "2",
   "sponsorName": "MediciNova",
   "title": "MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia",
   "nctId": "NCT05464784",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05464784",
     "quote": "NCT05464784 (MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor MediciNova.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/mn-001"
  },
  {
   "id": "nct05500222-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "resmetirom",
   "companyCik": "0001157601",
   "ticker": "MDGL",
   "indication": "NASH; Cirrhosis, Liver",
   "phase": "3",
   "sponsorName": "Madrigal Pharmaceuticals, Inc.",
   "title": "A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)",
   "nctId": "NCT05500222",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05500222",
     "quote": "NCT05500222 (A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/resmetirom"
  },
  {
   "id": "nct05500222-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "resmetirom",
   "companyCik": "0001157601",
   "ticker": "MDGL",
   "indication": "NASH; Cirrhosis, Liver",
   "phase": "3",
   "sponsorName": "Madrigal Pharmaceuticals, Inc.",
   "title": "A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)",
   "nctId": "NCT05500222",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05500222",
     "quote": "NCT05500222 (A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/resmetirom"
  },
  {
   "id": "nct05649748-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "treprostinil-palmitil",
   "companyCik": "0001104506",
   "ticker": "INSM",
   "indication": "Pulmonary Arterial Hypertension",
   "phase": "2/3",
   "sponsorName": "Insmed Incorporated",
   "title": "An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)",
   "nctId": "NCT05649748",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05649748",
     "quote": "NCT05649748 (An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Insmed Incorporated.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/treprostinil-palmitil"
  },
  {
   "id": "nct05672576-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "cenerimod",
   "companyCik": "0001792044",
   "ticker": "VTRS",
   "indication": "Lupus Erythematosus, Systemic",
   "phase": "3",
   "sponsorName": "Viatris Innovation GmbH",
   "title": "OPUS-2: A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus",
   "nctId": "NCT05672576",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05672576",
     "quote": "NCT05672576 (A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:48:32.313Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/cenerimod"
  },
  {
   "id": "nct05678673-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "xl092",
   "companyCik": "0000939767",
   "ticker": "EXEL",
   "indication": "Non-Clear Cell Renal Cell Carcinoma",
   "phase": "3",
   "sponsorName": "Exelixis",
   "title": "STELLAR-304: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma",
   "nctId": "NCT05678673",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05678673",
     "quote": "NCT05678673 (Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Exelixis.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/xl092"
  },
  {
   "id": "nct05692180-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "benralizumab",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "Asthma",
   "phase": "3",
   "sponsorName": "AstraZeneca",
   "title": "DOMINICA: A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma",
   "nctId": "NCT05692180",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05692180",
     "quote": "NCT05692180 (A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor AstraZeneca.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/benralizumab"
  },
  {
   "id": "nct05757869-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "milvexian",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Atrial Fibrillation",
   "phase": "3",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "LIBREXIA-AF: A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation",
   "nctId": "NCT05757869",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05757869",
     "quote": "NCT05757869 (A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/milvexian"
  },
  {
   "id": "nct05789056-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "qrx003-4-lotion",
   "companyCik": "0001671502",
   "ticker": "QNRX",
   "indication": "Netherton Syndrome",
   "phase": "2/3",
   "sponsorName": "Quoin Pharmaceuticals",
   "title": "Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome",
   "nctId": "NCT05789056",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05789056",
     "quote": "NCT05789056 (Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/qrx003-4-lotion"
  },
  {
   "id": "nct05849298-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "aaa617",
   "companyCik": "0001114448",
   "ticker": "NVS",
   "indication": "Prostatic Neoplasm",
   "phase": "2",
   "sponsorName": "Novartis Pharmaceuticals",
   "title": "PSMACare: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC",
   "nctId": "NCT05849298",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05849298",
     "quote": "NCT05849298 (A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/aaa617"
  },
  {
   "id": "nct05871970-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "tara-002",
   "companyCik": "0001359931",
   "ticker": "TARA",
   "indication": "Lymphatic Malformation",
   "phase": "2",
   "sponsorName": "Protara Therapeutics",
   "title": "STARBORN-1: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age",
   "nctId": "NCT05871970",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05871970",
     "quote": "NCT05871970 (Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Protara Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/tara-002"
  },
  {
   "id": "nct05871970-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "tara-002",
   "companyCik": "0001359931",
   "ticker": "TARA",
   "indication": "Lymphatic Malformation",
   "phase": "2",
   "sponsorName": "Protara Therapeutics",
   "title": "STARBORN-1: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age",
   "nctId": "NCT05871970",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05871970",
     "quote": "NCT05871970 (Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Protara Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/tara-002"
  },
  {
   "id": "nct05909397-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "palbociclib",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Breast Cancer",
   "phase": "3",
   "sponsorName": "Pfizer",
   "title": "VERITAC-3: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer",
   "nctId": "NCT05909397",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05909397",
     "quote": "NCT05909397 (Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/palbociclib"
  },
  {
   "id": "nct05922878-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "alto-300",
   "companyCik": "0001999480",
   "ticker": "ANRO",
   "indication": "Major Depressive Disorder",
   "phase": "2",
   "sponsorName": "Alto Neuroscience",
   "title": "Study of ALTO-300 in MDD",
   "nctId": "NCT05922878",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05922878",
     "quote": "NCT05922878 (Study of ALTO-300 in MDD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Alto Neuroscience.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/alto-300"
  },
  {
   "id": "nct05922878-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "alto-300",
   "companyCik": "0001999480",
   "ticker": "ANRO",
   "indication": "Major Depressive Disorder",
   "phase": "2",
   "sponsorName": "Alto Neuroscience",
   "title": "Study of ALTO-300 in MDD",
   "nctId": "NCT05922878",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05922878",
     "quote": "NCT05922878 (Study of ALTO-300 in MDD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Alto Neuroscience.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/alto-300"
  },
  {
   "id": "nct06038474-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-01",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "descartes-08",
   "companyCik": "0001453687",
   "ticker": "RNAC",
   "indication": "Systemic Lupus Erythematosus (SLE)",
   "phase": "2",
   "sponsorName": "Cartesian Therapeutics",
   "title": "SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus",
   "nctId": "NCT06038474",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06038474",
     "quote": "NCT06038474 (Descartes-08 for Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Cartesian Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/descartes-08"
  },
  {
   "id": "nct06038474-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "descartes-08",
   "companyCik": "0001453687",
   "ticker": "RNAC",
   "indication": "Systemic Lupus Erythematosus (SLE)",
   "phase": "2",
   "sponsorName": "Cartesian Therapeutics",
   "title": "SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus",
   "nctId": "NCT06038474",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06038474",
     "quote": "NCT06038474 (Descartes-08 for Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Cartesian Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/descartes-08"
  },
  {
   "id": "nct06052267-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "tev-56248",
   "companyCik": "0000818686",
   "ticker": "TEVA",
   "indication": "Asthma",
   "phase": "3",
   "sponsorName": "Teva Branded Pharmaceutical Products R&D LLC",
   "title": "A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations",
   "nctId": "NCT06052267",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06052267",
     "quote": "NCT06052267 (A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/tev-56248"
  },
  {
   "id": "nct06104566-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "lisaftoclax-btk-inhibitor",
   "companyCik": "0002023311",
   "ticker": "AAPG",
   "indication": "CLL/SLL",
   "phase": "3",
   "sponsorName": "Ascentage Pharma Group Inc.",
   "title": "Global Trial in APG2575 for Patients With CLL/SLL",
   "nctId": "NCT06104566",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06104566",
     "quote": "NCT06104566 (Global Trial in APG2575 for Patients With CLL/SLL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/lisaftoclax-btk-inhibitor"
  },
  {
   "id": "nct06107413-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "abbv-400",
   "companyCik": "0001551152",
   "ticker": "ABBV",
   "indication": "Unresectable Metastatic Colorectal Cancer",
   "phase": "2",
   "sponsorName": "AbbVie",
   "title": "Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab",
   "nctId": "NCT06107413",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06107413",
     "quote": "NCT06107413 (Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/abbv-400"
  },
  {
   "id": "nct06107413-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "abbv-400",
   "companyCik": "0001551152",
   "ticker": "ABBV",
   "indication": "Unresectable Metastatic Colorectal Cancer",
   "phase": "2",
   "sponsorName": "AbbVie",
   "title": "Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab",
   "nctId": "NCT06107413",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06107413",
     "quote": "NCT06107413 (Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/abbv-400"
  },
  {
   "id": "nct06122779-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "bms-986435",
   "companyCik": "0000014272",
   "ticker": "BMY",
   "indication": "Heart Failure",
   "phase": "2",
   "sponsorName": "Bristol-Myers Squibb",
   "title": "AURORA-HFpEF: Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)",
   "nctId": "NCT06122779",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06122779",
     "quote": "NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/bms-986435"
  },
  {
   "id": "nct06126224-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "karxt",
   "companyCik": "0000014272",
   "ticker": "BMY",
   "indication": "Psychosis Associated With Alzheimer's Disease",
   "phase": "3",
   "sponsorName": "Karuna Therapeutics, Inc., a Bristol Myers Squibb company",
   "title": "A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)",
   "nctId": "NCT06126224",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06126224",
     "quote": "NCT06126224 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-09 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/karxt"
  },
  {
   "id": "nct06132893-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "bhv-7000",
   "companyCik": "0001935979",
   "ticker": "BHVN",
   "indication": "Focal Epilepsy",
   "phase": "2/3",
   "sponsorName": "Biohaven Therapeutics Ltd.",
   "title": "RISE 2: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy",
   "nctId": "NCT06132893",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06132893",
     "quote": "NCT06132893 (A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/bhv-7000"
  },
  {
   "id": "nct06132893-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "bhv-7000",
   "companyCik": "0001935979",
   "ticker": "BHVN",
   "indication": "Focal Epilepsy",
   "phase": "2/3",
   "sponsorName": "Biohaven Therapeutics Ltd.",
   "title": "RISE 2: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy",
   "nctId": "NCT06132893",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06132893",
     "quote": "NCT06132893 (A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/bhv-7000"
  },
  {
   "id": "nct06212999-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "povorcitinib",
   "companyCik": "0000879169",
   "ticker": "INCY",
   "indication": "Hidradenitis Suppurativa (HS)",
   "phase": "3",
   "sponsorName": "Incyte Corporation",
   "title": "STOP-HS LTE: A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa",
   "nctId": "NCT06212999",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06212999",
     "quote": "NCT06212999 (A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-26 (ESTIMATED); Lead Sponsor Incyte Corporation.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/povorcitinib"
  },
  {
   "id": "nct06246110-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "eik1001",
   "companyCik": "0001861123",
   "ticker": "EIKN",
   "indication": "NSCLC",
   "phase": "2",
   "sponsorName": "Eikon Therapeutics",
   "title": "A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC",
   "nctId": "NCT06246110",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06246110",
     "quote": "NCT06246110 (A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eikon Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/eik1001"
  },
  {
   "id": "nct06246110-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "eik1001",
   "companyCik": "0001861123",
   "ticker": "EIKN",
   "indication": "NSCLC",
   "phase": "2",
   "sponsorName": "Eikon Therapeutics",
   "title": "A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC",
   "nctId": "NCT06246110",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06246110",
     "quote": "NCT06246110 (A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eikon Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/eik1001"
  },
  {
   "id": "nct06268886-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "bms-986446",
   "companyCik": "0000014272",
   "ticker": "BMY",
   "indication": "Alzheimer Disease, Early Onset",
   "phase": "2",
   "sponsorName": "Bristol-Myers Squibb",
   "title": "TargetTau-1: Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease",
   "nctId": "NCT06268886",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06268886",
     "quote": "NCT06268886 (Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/bms-986446"
  },
  {
   "id": "nct06269705-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "zilretta",
   "companyCik": "0001396814",
   "ticker": "PCRX",
   "indication": "Glenohumeral Osteoarthritis",
   "phase": "3",
   "sponsorName": "Pacira Pharmaceuticals, Inc",
   "title": "ZILRETTA in Subjects With Shoulder Osteoarthritis",
   "nctId": "NCT06269705",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06269705",
     "quote": "NCT06269705 (ZILRETTA in Subjects With Shoulder Osteoarthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Pacira Pharmaceuticals, Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/zilretta"
  },
  {
   "id": "nct06269705-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "zilretta",
   "companyCik": "0001396814",
   "ticker": "PCRX",
   "indication": "Glenohumeral Osteoarthritis",
   "phase": "3",
   "sponsorName": "Pacira Pharmaceuticals, Inc",
   "title": "ZILRETTA in Subjects With Shoulder Osteoarthritis",
   "nctId": "NCT06269705",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06269705",
     "quote": "NCT06269705 (ZILRETTA in Subjects With Shoulder Osteoarthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Pacira Pharmaceuticals, Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/zilretta"
  },
  {
   "id": "nct06274801-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "seralutinib",
   "companyCik": "0001728117",
   "ticker": "GOSS",
   "indication": "Pulmonary Arterial Hypertension",
   "phase": "3",
   "sponsorName": "Gossamer Bio USA, Inc.",
   "title": "Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)",
   "nctId": "NCT06274801",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06274801",
     "quote": "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/seralutinib"
  },
  {
   "id": "nct06274801-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "seralutinib",
   "companyCik": "0001728117",
   "ticker": "GOSS",
   "indication": "Pulmonary Arterial Hypertension",
   "phase": "3",
   "sponsorName": "Gossamer Bio USA, Inc.",
   "title": "Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)",
   "nctId": "NCT06274801",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06274801",
     "quote": "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/seralutinib"
  },
  {
   "id": "nct06298955-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "oms906-study-drug",
   "companyCik": "0001285819",
   "ticker": "OMER",
   "indication": "Paroxysmal Nocturnal Hemoglobinuria",
   "phase": "2",
   "sponsorName": "Omeros Corporation",
   "title": "Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria",
   "nctId": "NCT06298955",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06298955",
     "quote": "NCT06298955 (Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Omeros Corporation.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/oms906-study-drug"
  },
  {
   "id": "nct06298955-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "oms906-study-drug",
   "companyCik": "0001285819",
   "ticker": "OMER",
   "indication": "Paroxysmal Nocturnal Hemoglobinuria",
   "phase": "2",
   "sponsorName": "Omeros Corporation",
   "title": "Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria",
   "nctId": "NCT06298955",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06298955",
     "quote": "NCT06298955 (Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Omeros Corporation.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/oms906-study-drug"
  },
  {
   "id": "nct06317311-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "dostarlimab",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Carcinoma",
   "phase": "2",
   "sponsorName": "GlaxoSmithKline",
   "title": "RUBY-J: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer",
   "nctId": "NCT06317311",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06317311",
     "quote": "NCT06317311 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/dostarlimab"
  },
  {
   "id": "nct06388941-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "iptacopan",
   "companyCik": "0001114448",
   "ticker": "NVS",
   "indication": "Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis",
   "phase": "2",
   "sponsorName": "Novartis Pharmaceuticals",
   "title": "Iptacopan in Patients With ANCA Associated Vasculitis",
   "nctId": "NCT06388941",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06388941",
     "quote": "NCT06388941 (Iptacopan in Patients With ANCA Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/iptacopan"
  },
  {
   "id": "nct06413433-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "solriamfetol",
   "companyCik": "0001579428",
   "ticker": "AXSM",
   "indication": "Binge-Eating Disorder",
   "phase": "3",
   "sponsorName": "Axsome Therapeutics, Inc.",
   "title": "ENGAGE: Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol",
   "nctId": "NCT06413433",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06413433",
     "quote": "NCT06413433 (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/solriamfetol"
  },
  {
   "id": "nct06421636-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "regn7999",
   "companyCik": "0000872589",
   "ticker": "REGN",
   "indication": "Non-Transfusion Dependent Beta-Thalassemia (NTDT)",
   "phase": "2",
   "sponsorName": "Regeneron Pharmaceuticals",
   "title": "FERVENT-1: A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body",
   "nctId": "NCT06421636",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06421636",
     "quote": "NCT06421636 (A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/regn7999"
  },
  {
   "id": "nct06430866-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "abp-234",
   "companyCik": "0000318154",
   "ticker": "AMGN",
   "indication": "Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)",
   "phase": "3",
   "sponsorName": "Amgen",
   "title": "Eucalyptus: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)",
   "nctId": "NCT06430866",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06430866",
     "quote": "NCT06430866 (Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Amgen.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/abp-234"
  },
  {
   "id": "nct06443463-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "bhv-7000",
   "companyCik": "0001935979",
   "ticker": "BHVN",
   "indication": "Focal Epilepsy",
   "phase": "2",
   "sponsorName": "Biohaven Therapeutics Ltd.",
   "title": "Long-term Safety and Tolerability of BHV-7000",
   "nctId": "NCT06443463",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06443463",
     "quote": "NCT06443463 (Long-term Safety and Tolerability of BHV-7000): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/bhv-7000"
  },
  {
   "id": "nct06443463-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "bhv-7000",
   "companyCik": "0001935979",
   "ticker": "BHVN",
   "indication": "Focal Epilepsy",
   "phase": "2",
   "sponsorName": "Biohaven Therapeutics Ltd.",
   "title": "Long-term Safety and Tolerability of BHV-7000",
   "nctId": "NCT06443463",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06443463",
     "quote": "NCT06443463 (Long-term Safety and Tolerability of BHV-7000): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/bhv-7000"
  },
  {
   "id": "nct06456593-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "obefazimod",
   "companyCik": "0001956827",
   "ticker": "ABVX",
   "indication": "Moderately to Severely Active Crohn Disease",
   "phase": "2",
   "sponsorName": "Abivax S.A.",
   "title": "ENHANCE-CD: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease",
   "nctId": "NCT06456593",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06456593",
     "quote": "NCT06456593 (Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Abivax S.A..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/obefazimod"
  },
  {
   "id": "nct06468228-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "lutikizumab",
   "companyCik": "0001551152",
   "ticker": "ABBV",
   "indication": "Hidradenitis Suppurativa",
   "phase": "3",
   "sponsorName": "AbbVie",
   "title": "Intrepid: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa",
   "nctId": "NCT06468228",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06468228",
     "quote": "NCT06468228 (A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/lutikizumab"
  },
  {
   "id": "nct06468228-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "lutikizumab",
   "companyCik": "0001551152",
   "ticker": "ABBV",
   "indication": "Hidradenitis Suppurativa",
   "phase": "3",
   "sponsorName": "AbbVie",
   "title": "Intrepid: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa",
   "nctId": "NCT06468228",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06468228",
     "quote": "NCT06468228 (A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/lutikizumab"
  },
  {
   "id": "nct06500702-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "rilzabrutinib",
   "companyCik": "0001121404",
   "ticker": "SNY",
   "indication": "Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion",
   "phase": "2",
   "sponsorName": "Sanofi",
   "title": "RESULT: A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease",
   "nctId": "NCT06500702",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06500702",
     "quote": "NCT06500702 (A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Sanofi.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/rilzabrutinib"
  },
  {
   "id": "nct06537999-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "claseprubart",
   "companyCik": "0001690585",
   "ticker": "DNTH",
   "indication": "Multifocal Motor Neuropathy",
   "phase": "2",
   "sponsorName": "Dianthus Therapeutics",
   "title": "MOMENTUM: A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy",
   "nctId": "NCT06537999",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06537999",
     "quote": "NCT06537999 (A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Dianthus Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/claseprubart"
  },
  {
   "id": "nct06544616-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "jnj-64042056",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Alzheimer Disease",
   "phase": "2",
   "sponsorName": "Janssen Pharmaceutica N.V., Belgium",
   "title": "Reτain: A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease",
   "nctId": "NCT06544616",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06544616",
     "quote": "NCT06544616 (A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-22 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/jnj-64042056"
  },
  {
   "id": "nct06559306-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "seltorexant",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Depressive Disorder, Major",
   "phase": "3",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms",
   "nctId": "NCT06559306",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06559306",
     "quote": "NCT06559306 (Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/seltorexant"
  },
  {
   "id": "nct06568367-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "solriamfetol",
   "companyCik": "0001579428",
   "ticker": "AXSM",
   "indication": "Excessive Sleepiness; Shift-work Disorder",
   "phase": "3",
   "sponsorName": "Axsome Therapeutics, Inc.",
   "title": "Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)",
   "nctId": "NCT06568367",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06568367",
     "quote": "NCT06568367 (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/solriamfetol"
  },
  {
   "id": "nct06568627-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "escharex-ex-03",
   "companyCik": "0001593984",
   "ticker": "MDWD",
   "indication": "Venous Leg Ulcer (VLU)",
   "phase": "3",
   "sponsorName": "MediWound Ltd",
   "title": "VALUE: A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)",
   "nctId": "NCT06568627",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06568627",
     "quote": "NCT06568627 (A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor MediWound Ltd.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/escharex-ex-03"
  },
  {
   "id": "nct06568627-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "escharex-ex-03",
   "companyCik": "0001593984",
   "ticker": "MDWD",
   "indication": "Venous Leg Ulcer (VLU)",
   "phase": "3",
   "sponsorName": "MediWound Ltd",
   "title": "VALUE: A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)",
   "nctId": "NCT06568627",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06568627",
     "quote": "NCT06568627 (A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor MediWound Ltd.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/escharex-ex-03"
  },
  {
   "id": "nct06607458-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "melphalan-hds-followed-by-consolidation-treatment-with-trifluridine-tipiracil-pl",
   "companyCik": "0000872912",
   "ticker": "DCTH",
   "indication": "Refractory Metastatic Colorectal Cancer",
   "phase": "2",
   "sponsorName": "Delcath Systems Inc.",
   "title": "DEL-LIVER: Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease",
   "nctId": "NCT06607458",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06607458",
     "quote": "NCT06607458 (Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Delcath Systems Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/melphalan-hds-followed-by-consolidation-treatment-with-trifluridine-tipiracil-pl"
  },
  {
   "id": "nct06607458-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "melphalan-hds-followed-by-consolidation-treatment-with-trifluridine-tipiracil-pl",
   "companyCik": "0000872912",
   "ticker": "DCTH",
   "indication": "Refractory Metastatic Colorectal Cancer",
   "phase": "2",
   "sponsorName": "Delcath Systems Inc.",
   "title": "DEL-LIVER: Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease",
   "nctId": "NCT06607458",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06607458",
     "quote": "NCT06607458 (Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Delcath Systems Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/melphalan-hds-followed-by-consolidation-treatment-with-trifluridine-tipiracil-pl"
  },
  {
   "id": "nct06607627-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "gefurulimab",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "Generalized Myasthenia Gravis; gMG",
   "phase": "3",
   "sponsorName": "Alexion Pharmaceuticals, Inc.",
   "title": "PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis",
   "nctId": "NCT06607627",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06607627",
     "quote": "NCT06607627 (PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/gefurulimab"
  },
  {
   "id": "nct06685757-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-01",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "felzartamab",
   "companyCik": "0000875045",
   "ticker": "BIIB",
   "indication": "Antibody-mediated Rejection",
   "phase": "3",
   "sponsorName": "Biogen",
   "title": "TRANSCEND: A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)",
   "nctId": "NCT06685757",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06685757",
     "quote": "NCT06685757 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Biogen.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/felzartamab"
  },
  {
   "id": "nct06685757-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "felzartamab",
   "companyCik": "0000875045",
   "ticker": "BIIB",
   "indication": "Antibody-mediated Rejection",
   "phase": "3",
   "sponsorName": "Biogen",
   "title": "TRANSCEND: A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)",
   "nctId": "NCT06685757",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06685757",
     "quote": "NCT06685757 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Biogen.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/875045/000119312526222908/d109852dex991.htm",
     "accession": "0001193125-26-222908",
     "quote": "Apellis also brings an established nephrology commercial and medical infrastructure to accelerate Biogen's launch readiness for felzartamab, with a first Phase 3 readout in antibody-mediated rejection in kidney transplant patients anticipated in the first half of 2027.",
     "fetchedAt": "2026-11-12T05:58:11.202Z",
     "filedAt": "2026-05-14",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/875045/000119312526134889/d14986dex992.htm",
     "accession": "0001193125-26-134889",
     "quote": "| More | felzartamab, which is currently in Phase 3 studies for three kidney diseases with the first trial readout expected in the first half of 2027.",
     "fetchedAt": "2026-11-12T05:58:39.002Z",
     "filedAt": "2026-03-31",
     "form": "8-K"
    }
   ],
   "firstSeen": "2026-03-31",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "confidence": 0.78,
   "pageUrl": "https://sec-api.dev/pdufa/felzartamab"
  },
  {
   "id": "nct06695845-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "zanidatamab",
   "companyCik": "0001232524",
   "ticker": "JAZZ",
   "indication": "Breast Cancer; Gastric Cancer; Esophageal Cancer",
   "phase": "2",
   "sponsorName": "Jazz Pharmaceuticals",
   "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",
   "nctId": "NCT06695845",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06695845",
     "quote": "NCT06695845 (A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/zanidatamab"
  },
  {
   "id": "nct06724809-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "eculizumab",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "NMOSD; Neuromyelitis Optica Spectrum Disorders",
   "phase": "3",
   "sponsorName": "Alexion Pharmaceuticals, Inc.",
   "title": "ECU-NMO-304: Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD",
   "nctId": "NCT06724809",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06724809",
     "quote": "NCT06724809 (Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-07 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/eculizumab"
  },
  {
   "id": "nct06740630-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "pcv-20",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Chickenpox",
   "phase": "3",
   "sponsorName": "GlaxoSmithKline",
   "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age",
   "nctId": "NCT06740630",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06740630",
     "quote": "NCT06740630 (A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/pcv-20"
  },
  {
   "id": "nct06799247-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "decartes-08",
   "companyCik": "0001453687",
   "ticker": "RNAC",
   "indication": "Myasthaenia Gravis",
   "phase": "3",
   "sponsorName": "Cartesian Therapeutics",
   "title": "Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis",
   "nctId": "NCT06799247",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06799247",
     "quote": "NCT06799247 (Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Cartesian Therapeutics.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/decartes-08"
  },
  {
   "id": "nct06806137-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "pcv-20",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Chickenpox",
   "phase": "3",
   "sponsorName": "GlaxoSmithKline",
   "title": "A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age",
   "nctId": "NCT06806137",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06806137",
     "quote": "NCT06806137 (A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/pcv-20"
  },
  {
   "id": "nct06838000-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-01",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "pcv21",
   "companyCik": "0001121404",
   "ticker": "SNY",
   "indication": "Pneumococcal Infections",
   "phase": "3",
   "sponsorName": "Sanofi Pasteur, a Sanofi Company",
   "title": "Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents",
   "nctId": "NCT06838000",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06838000",
     "quote": "NCT06838000 (Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/pcv21"
  },
  {
   "id": "nct06838000-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "pcv21",
   "companyCik": "0001121404",
   "ticker": "SNY",
   "indication": "Pneumococcal Infections",
   "phase": "3",
   "sponsorName": "Sanofi Pasteur, a Sanofi Company",
   "title": "Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents",
   "nctId": "NCT06838000",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06838000",
     "quote": "NCT06838000 (Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/pcv21"
  },
  {
   "id": "nct06848348-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "halneuron",
   "companyCik": "0001818844",
   "ticker": "DWTX",
   "phase": "2",
   "sponsorName": "Dogwood Therapeutics Inc.",
   "title": "Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain",
   "nctId": "NCT06848348",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06848348",
     "quote": "NCT06848348 (Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Dogwood Therapeutics Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/halneuron"
  },
  {
   "id": "nct06848348-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "halneuron",
   "companyCik": "0001818844",
   "ticker": "DWTX",
   "phase": "2",
   "sponsorName": "Dogwood Therapeutics Inc.",
   "title": "Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain",
   "nctId": "NCT06848348",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06848348",
     "quote": "NCT06848348 (Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Dogwood Therapeutics Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/halneuron"
  },
  {
   "id": "nct06953466-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "qrx003-4-lotion",
   "companyCik": "0001671502",
   "ticker": "QNRX",
   "indication": "Netherton Syndrome",
   "phase": "2/3",
   "sponsorName": "Quoin Pharmaceuticals",
   "title": "Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome",
   "nctId": "NCT06953466",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06953466",
     "quote": "NCT06953466 (Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/qrx003-4-lotion"
  },
  {
   "id": "nct06958536-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "brivekimig",
   "companyCik": "0001121404",
   "ticker": "SNY",
   "indication": "Crohn's Disease",
   "phase": "2",
   "sponsorName": "Sanofi",
   "title": "CHROMA CD: A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease",
   "nctId": "NCT06958536",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06958536",
     "quote": "NCT06958536 (A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/brivekimig"
  },
  {
   "id": "nct06972264-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "vdphl01",
   "companyCik": "0001827635",
   "ticker": "MANE",
   "indication": "Androgenetic Alopecia; AGA; Male Pattern Baldness",
   "phase": "3",
   "sponsorName": "Veradermics, Inc.",
   "title": "Safety and Efficacy of VDPHL01 in Males With AGA",
   "nctId": "NCT06972264",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06972264",
     "quote": "NCT06972264 (Safety and Efficacy of VDPHL01 in Males With AGA): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Veradermics, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/vdphl01"
  },
  {
   "id": "nct06972264-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "vdphl01",
   "companyCik": "0001827635",
   "ticker": "MANE",
   "indication": "Androgenetic Alopecia; AGA; Male Pattern Baldness",
   "phase": "3",
   "sponsorName": "Veradermics, Inc.",
   "title": "Safety and Efficacy of VDPHL01 in Males With AGA",
   "nctId": "NCT06972264",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06972264",
     "quote": "NCT06972264 (Safety and Efficacy of VDPHL01 in Males With AGA): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Veradermics, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/vdphl01"
  },
  {
   "id": "nct06975722-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "brivekimig",
   "companyCik": "0001121404",
   "ticker": "SNY",
   "indication": "Ulcerative Colitis",
   "phase": "2",
   "sponsorName": "Sanofi",
   "title": "COLOR UC: A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis",
   "nctId": "NCT06975722",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06975722",
     "quote": "NCT06975722 (A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/brivekimig"
  },
  {
   "id": "nct06991556-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "luxdegalutamide",
   "companyCik": "0001114448",
   "ticker": "NVS",
   "indication": "Metastatic Hormone-sensitive Prostate Cancer",
   "phase": "2",
   "sponsorName": "Novartis Pharmaceuticals",
   "title": "An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
   "nctId": "NCT06991556",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06991556",
     "quote": "NCT06991556 (An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/luxdegalutamide"
  },
  {
   "id": "nct07010471-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "companyCik": "0001689548",
   "ticker": "PRAX",
   "indication": "Developmental and Epileptic Encephalopathy 1",
   "phase": "3",
   "sponsorName": "Praxis Precision Medicines",
   "title": "EMERALD: A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine",
   "nctId": "NCT07010471",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07010471",
     "quote": "NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/companies/prax/catalysts"
  },
  {
   "id": "nct07010471-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "companyCik": "0001689548",
   "ticker": "PRAX",
   "indication": "Developmental and Epileptic Encephalopathy 1",
   "phase": "3",
   "sponsorName": "Praxis Precision Medicines",
   "title": "EMERALD: A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine",
   "nctId": "NCT07010471",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07010471",
     "quote": "NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/companies/prax/catalysts"
  },
  {
   "id": "nct07015437-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "companyCik": "0001020214",
   "ticker": "CERS",
   "indication": "Healthy Subjects",
   "phase": "2",
   "sponsorName": "Cerus Corporation",
   "title": "A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1",
   "nctId": "NCT07015437",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07015437",
     "quote": "NCT07015437 (A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Cerus Corporation.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/companies/cers/catalysts"
  },
  {
   "id": "nct07016750-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "kb803",
   "companyCik": "0001711279",
   "ticker": "KRYS",
   "phase": "3",
   "sponsorName": "Krystal Biotech, Inc.",
   "title": "IOLITE: A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa",
   "nctId": "NCT07016750",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07016750",
     "quote": "NCT07016750 (A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Krystal Biotech, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/kb803"
  },
  {
   "id": "nct07019922-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "companyCik": "0001689548",
   "ticker": "PRAX",
   "indication": "Epileptic Encephalopathy; SCN2A Encephalopathy",
   "phase": "3",
   "sponsorName": "Praxis Precision Medicines",
   "title": "A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety",
   "nctId": "NCT07019922",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07019922",
     "quote": "NCT07019922 (A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/companies/prax/catalysts"
  },
  {
   "id": "nct07019922-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "companyCik": "0001689548",
   "ticker": "PRAX",
   "indication": "Epileptic Encephalopathy; SCN2A Encephalopathy",
   "phase": "3",
   "sponsorName": "Praxis Precision Medicines",
   "title": "A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety",
   "nctId": "NCT07019922",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07019922",
     "quote": "NCT07019922 (A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/companies/prax/catalysts"
  },
  {
   "id": "nct07029711-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "ritlecitinib-higher-dose",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Severe Alopecia Areata",
   "phase": "3",
   "sponsorName": "Pfizer",
   "title": "B7981027: A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata",
   "nctId": "NCT07029711",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07029711",
     "quote": "NCT07029711 (A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-02 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/ritlecitinib-higher-dose"
  },
  {
   "id": "nct07037277-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "bemnifosbuvir-ruzasvir",
   "companyCik": "0001593899",
   "ticker": "AVIR",
   "indication": "HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection",
   "phase": "3",
   "sponsorName": "Atea Pharmaceuticals, Inc.",
   "title": "C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV",
   "nctId": "NCT07037277",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07037277",
     "quote": "NCT07037277 (C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Atea Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/bemnifosbuvir-ruzasvir"
  },
  {
   "id": "nct07037277-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "bemnifosbuvir-ruzasvir",
   "companyCik": "0001593899",
   "ticker": "AVIR",
   "indication": "HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection",
   "phase": "3",
   "sponsorName": "Atea Pharmaceuticals, Inc.",
   "title": "C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV",
   "nctId": "NCT07037277",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07037277",
     "quote": "NCT07037277 (C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Atea Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/bemnifosbuvir-ruzasvir"
  },
  {
   "id": "nct07055295-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "rabies-vaccine-serum-free-vero-cell-freeze-dried",
   "companyCik": "0001084201",
   "ticker": "SVA",
   "indication": "Rabies",
   "phase": "3",
   "sponsorName": "Sinovac Biotech Co., Ltd",
   "title": "Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen",
   "nctId": "NCT07055295",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07055295",
     "quote": "NCT07055295 (Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Sinovac Biotech Co., Ltd.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/rabies-vaccine-serum-free-vero-cell-freeze-dried"
  },
  {
   "id": "nct07128550-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "tobevibart",
   "companyCik": "0001706431",
   "ticker": "VIR",
   "indication": "Viral Hepatitis",
   "phase": "3",
   "sponsorName": "Vir Biotechnology, Inc.",
   "title": "A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide",
   "nctId": "NCT07128550",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07128550",
     "quote": "NCT07128550 (A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vir Biotechnology, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/tobevibart"
  },
  {
   "id": "nct07128550-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "tobevibart",
   "companyCik": "0001706431",
   "ticker": "VIR",
   "indication": "Viral Hepatitis",
   "phase": "3",
   "sponsorName": "Vir Biotechnology, Inc.",
   "title": "A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide",
   "nctId": "NCT07128550",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07128550",
     "quote": "NCT07128550 (A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vir Biotechnology, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/tobevibart"
  },
  {
   "id": "nct07169851-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "ly3537021",
   "companyCik": "0000059478",
   "ticker": "LLY",
   "indication": "Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions",
   "phase": "2",
   "sponsorName": "Eli Lilly and Company",
   "title": "A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer",
   "nctId": "NCT07169851",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07169851",
     "quote": "NCT07169851 (A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/ly3537021"
  },
  {
   "id": "nct07169851-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "ly3537021",
   "companyCik": "0000059478",
   "ticker": "LLY",
   "indication": "Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions",
   "phase": "2",
   "sponsorName": "Eli Lilly and Company",
   "title": "A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer",
   "nctId": "NCT07169851",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07169851",
     "quote": "NCT07169851 (A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/ly3537021"
  },
  {
   "id": "nct07184632-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "nnc0662-0419",
   "companyCik": "0000353278",
   "ticker": "NVO",
   "indication": "Overweight; Obesity",
   "phase": "2",
   "sponsorName": "Novo Nordisk A/S",
   "title": "A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity",
   "nctId": "NCT07184632",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07184632",
     "quote": "NCT07184632 (A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/nnc0662-0419"
  },
  {
   "id": "nct07194382-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "ap02",
   "companyCik": "0001540171",
   "ticker": "AVLN",
   "indication": "Idiopathic Pulmonary Fibrosis (IPF)",
   "phase": "2",
   "sponsorName": "Avalyn Pharma Inc.",
   "title": "AURA-IPF: AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF",
   "nctId": "NCT07194382",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07194382",
     "quote": "NCT07194382 (AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Avalyn Pharma Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/ap02"
  },
  {
   "id": "nct07194382-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "ap02",
   "companyCik": "0001540171",
   "ticker": "AVLN",
   "indication": "Idiopathic Pulmonary Fibrosis (IPF)",
   "phase": "2",
   "sponsorName": "Avalyn Pharma Inc.",
   "title": "AURA-IPF: AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF",
   "nctId": "NCT07194382",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07194382",
     "quote": "NCT07194382 (AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Avalyn Pharma Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/ap02"
  },
  {
   "id": "nct07219615-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "ritlecitinib",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Chronic Spontaneous Urticaria",
   "phase": "2",
   "sponsorName": "Pfizer",
   "title": "A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.",
   "nctId": "NCT07219615",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07219615",
     "quote": "NCT07219615 (A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/ritlecitinib"
  },
  {
   "id": "nct07221578-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "vqw-765",
   "companyCik": "0001347178",
   "ticker": "VNDA",
   "indication": "Social Anxiety Disorder (SAD)",
   "phase": "3",
   "sponsorName": "Vanda Pharmaceuticals",
   "title": "Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder",
   "nctId": "NCT07221578",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07221578",
     "quote": "NCT07221578 (Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/vqw-765"
  },
  {
   "id": "nct07221578-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "vqw-765",
   "companyCik": "0001347178",
   "ticker": "VNDA",
   "indication": "Social Anxiety Disorder (SAD)",
   "phase": "3",
   "sponsorName": "Vanda Pharmaceuticals",
   "title": "Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder",
   "nctId": "NCT07221578",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07221578",
     "quote": "NCT07221578 (Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/vqw-765"
  },
  {
   "id": "nct07222917-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "baxdrostat-dapagliflozin",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "Chronic Kidney Disease and Hypertension",
   "phase": "2",
   "sponsorName": "AstraZeneca",
   "title": "BaxDuo-Baltic: A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.",
   "nctId": "NCT07222917",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07222917",
     "quote": "NCT07222917 (A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-10 (ESTIMATED); Lead Sponsor AstraZeneca.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/baxdrostat-dapagliflozin"
  },
  {
   "id": "nct07226661-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "spn-821",
   "companyCik": "0001625297",
   "ticker": "SUPN",
   "indication": "Major Depressive Disorder (MDD)",
   "phase": "2",
   "sponsorName": "Supernus Pharmaceuticals, Inc.",
   "title": "Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder",
   "nctId": "NCT07226661",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07226661",
     "quote": "NCT07226661 (Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/spn-821"
  },
  {
   "id": "nct07228390-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "ritlecitinib",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Hidradenitis Suppurativa",
   "phase": "2",
   "sponsorName": "Pfizer",
   "title": "A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.",
   "nctId": "NCT07228390",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07228390",
     "quote": "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/ritlecitinib"
  },
  {
   "id": "nct07363720-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "tak-861",
   "companyCik": "0001395064",
   "ticker": "TAK",
   "indication": "Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy",
   "phase": "3",
   "sponsorName": "Takeda",
   "title": "A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy",
   "nctId": "NCT07363720",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07363720",
     "quote": "NCT07363720 (A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Takeda.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/tak-861"
  },
  {
   "id": "nct07371650-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "trx-100",
   "companyCik": "0001130598",
   "ticker": "TRAW",
   "indication": "Influenza",
   "phase": "2",
   "sponsorName": "Traws Pharma, Inc.",
   "title": "This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza",
   "nctId": "NCT07371650",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07371650",
     "quote": "NCT07371650 (This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Traws Pharma, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/trx-100"
  },
  {
   "id": "nct07371650-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "trx-100",
   "companyCik": "0001130598",
   "ticker": "TRAW",
   "indication": "Influenza",
   "phase": "2",
   "sponsorName": "Traws Pharma, Inc.",
   "title": "This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza",
   "nctId": "NCT07371650",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07371650",
     "quote": "NCT07371650 (This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Traws Pharma, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/trx-100"
  },
  {
   "id": "nct07402876-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "icm-adx-2191",
   "companyCik": "0001341235",
   "ticker": "ALDX",
   "indication": "Primary Vitreoretinal Lymphoma",
   "phase": "3",
   "sponsorName": "Aldeyra Therapeutics, Inc.",
   "title": "A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma",
   "nctId": "NCT07402876",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07402876",
     "quote": "NCT07402876 (A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Aldeyra Therapeutics, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/icm-adx-2191"
  },
  {
   "id": "nct07402876-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "icm-adx-2191",
   "companyCik": "0001341235",
   "ticker": "ALDX",
   "indication": "Primary Vitreoretinal Lymphoma",
   "phase": "3",
   "sponsorName": "Aldeyra Therapeutics, Inc.",
   "title": "A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma",
   "nctId": "NCT07402876",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07402876",
     "quote": "NCT07402876 (A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Aldeyra Therapeutics, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/icm-adx-2191"
  },
  {
   "id": "nct07443202-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "lotilaner",
   "companyCik": "0001819790",
   "ticker": "TARS",
   "indication": "Ocular Rosacea",
   "phase": "2",
   "sponsorName": "Tarsus Pharmaceuticals, Inc.",
   "title": "Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)",
   "nctId": "NCT07443202",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07443202",
     "quote": "NCT07443202 (Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/lotilaner"
  },
  {
   "id": "nct07446439-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-01",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "tradipitant",
   "companyCik": "0001347178",
   "ticker": "VNDA",
   "indication": "Nausea and Vomiting; Obesity",
   "phase": "3",
   "sponsorName": "Vanda Pharmaceuticals",
   "title": "A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use",
   "nctId": "NCT07446439",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07446439",
     "quote": "NCT07446439 (A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/tradipitant"
  },
  {
   "id": "nct07446439-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "tradipitant",
   "companyCik": "0001347178",
   "ticker": "VNDA",
   "indication": "Nausea and Vomiting; Obesity",
   "phase": "3",
   "sponsorName": "Vanda Pharmaceuticals",
   "title": "A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use",
   "nctId": "NCT07446439",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07446439",
     "quote": "NCT07446439 (A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/tradipitant"
  },
  {
   "id": "nct07477704-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "alirocumab",
   "companyCik": "0000872589",
   "ticker": "REGN",
   "indication": "Hypercholesterolemia",
   "phase": "2",
   "sponsorName": "Regeneron Pharmaceuticals",
   "title": "ASCEND-QW: A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia",
   "nctId": "NCT07477704",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07477704",
     "quote": "NCT07477704 (A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/alirocumab"
  },
  {
   "id": "nct07482657-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "zelicapavir",
   "companyCik": "0001177648",
   "ticker": "ENTA",
   "indication": "RSV Infection; RSV; Respiratory Syncytial Virus (RSV)",
   "phase": "2",
   "sponsorName": "Enanta Pharmaceuticals, Inc",
   "title": "A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus",
   "nctId": "NCT07482657",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07482657",
     "quote": "NCT07482657 (A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Enanta Pharmaceuticals, Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/zelicapavir"
  },
  {
   "id": "nct07482657-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "zelicapavir",
   "companyCik": "0001177648",
   "ticker": "ENTA",
   "indication": "RSV Infection; RSV; Respiratory Syncytial Virus (RSV)",
   "phase": "2",
   "sponsorName": "Enanta Pharmaceuticals, Inc",
   "title": "A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus",
   "nctId": "NCT07482657",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07482657",
     "quote": "NCT07482657 (A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Enanta Pharmaceuticals, Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm",
     "accession": "0001193125-26-342336",
     "quote": "Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027",
     "fetchedAt": "2026-11-12T05:57:43.861Z",
     "filedAt": "2026-08-10",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm",
     "accession": "0001193125-26-342336",
     "quote": "On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027",
     "fetchedAt": "2026-11-12T05:57:43.861Z",
     "filedAt": "2026-08-10",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm",
     "accession": "0001193125-26-342336",
     "quote": "\"Dosing began in LOTUS, our Phase 2b trial of zelicapavir in pediatric patients with RSV in Thailand, with topline data anticipated in 2027.",
     "fetchedAt": "2026-11-12T05:57:43.861Z",
     "filedAt": "2026-08-10",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/d159604dex991.htm",
     "accession": "0001193125-26-274950",
     "quote": "Enanta also announced plans to initiate a Phase 2b clinical trial of zelicapavir in pediatric patients with RSV, with topline data expected in 2027.",
     "fetchedAt": "2026-11-12T05:58:02.497Z",
     "filedAt": "2026-06-18",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm",
     "accession": "0001193125-26-342336",
     "quote": "Topline Phase 2b data from RESOLVE is expected in 2027.",
     "fetchedAt": "2026-11-12T05:57:43.861Z",
     "filedAt": "2026-08-10",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/d159604dex991.htm",
     "accession": "0001193125-26-274950",
     "quote": "The Phase 2b portion of the trial will confirm the treatment effect with topline data expected in 2027.",
     "fetchedAt": "2026-11-12T05:58:02.497Z",
     "filedAt": "2026-06-18",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/d159604dex991.htm",
     "accession": "0001193125-26-274950",
     "quote": "Enanta plans to initiate this Phase 2b study in the third quarter of 2026 with topline data expected in 2027.",
     "fetchedAt": "2026-11-12T05:58:02.497Z",
     "filedAt": "2026-06-18",
     "form": "8-K"
    },
    {
     "kind": "sec_424b",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526294828/d17914d424b5.htm",
     "accession": "0001193125-26-294828",
     "quote": "The Company expects to initiate this Phase 2b study in the third quarter of 2026 with topline data targeted for 2027.",
     "fetchedAt": "2026-11-12T05:58:00.312Z",
     "filedAt": "2026-07-02",
     "form": "424B5"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/d159604dex991.htm",
     "accession": "0001193125-26-274950",
     "quote": "We plan to initiate this pediatric study in the third quarter of 2026, with topline data expected in 2027.\"",
     "fetchedAt": "2026-11-12T05:58:02.497Z",
     "filedAt": "2026-06-18",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/enta-20260630.htm",
     "accession": "0001193125-26-345719",
     "quote": "We initiated this pediatric study named LOTUS and dosed our first participant in the third quarter of 2026, with topline data expected in 2027.",
     "fetchedAt": "2026-11-12T05:57:40.290Z",
     "filedAt": "2026-08-12",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-06-18",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "confidence": 0.81,
   "pageUrl": "https://sec-api.dev/pdufa/zelicapavir"
  },
  {
   "id": "nct07500506-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "vla15",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Lyme Disease",
   "phase": "3",
   "sponsorName": "Pfizer",
   "title": "A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine",
   "nctId": "NCT07500506",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07500506",
     "quote": "NCT07500506 (A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-04 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/vla15"
  },
  {
   "id": "nct07511361-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "tonlamarsen",
   "companyCik": "0002123613",
   "ticker": "KARD",
   "indication": "Hypertension; Acute Severe Hypertension; Hypertensive Emergency",
   "phase": "2",
   "sponsorName": "Kardigan, Inc.",
   "title": "KARDINAL-ASH: Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension",
   "nctId": "NCT07511361",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07511361",
     "quote": "NCT07511361 (Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kardigan, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/tonlamarsen"
  },
  {
   "id": "nct07511361-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "tonlamarsen",
   "companyCik": "0002123613",
   "ticker": "KARD",
   "indication": "Hypertension; Acute Severe Hypertension; Hypertensive Emergency",
   "phase": "2",
   "sponsorName": "Kardigan, Inc.",
   "title": "KARDINAL-ASH: Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension",
   "nctId": "NCT07511361",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07511361",
     "quote": "NCT07511361 (Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kardigan, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/2123613/000119312526343395/ck0002123613-ex99_1.htm",
     "accession": "0001193125-26-343395",
     "quote": "In the second quarter, the Company randomized the first patient in KARDINAL-ASH and expects to share Phase 2 topline data in the first half of 2027.",
     "fetchedAt": "2026-11-12T05:57:42.561Z",
     "filedAt": "2026-08-11",
     "form": "8-K"
    },
    {
     "kind": "sec_424b",
     "url": "https://www.sec.gov/Archives/edgar/data/2123613/000119312526276096/d107928d424b4.htm",
     "accession": "0001193125-26-276096",
     "quote": "We anticipate sharing topline data from the Phase 2b portion of KARDINAL-ASH in the first half of 2027.",
     "fetchedAt": "2026-11-12T05:58:02.540Z",
     "filedAt": "2026-06-18",
     "form": "424B4"
    },
    {
     "kind": "sec_424b",
     "url": "https://www.sec.gov/Archives/edgar/data/2123613/000119312526276096/d107928d424b4.htm",
     "accession": "0001193125-26-276096",
     "quote": "We anticipate sharing Phase 2b topline data from KARDINAL-ASH in the first half of 2027.",
     "fetchedAt": "2026-11-12T05:58:02.540Z",
     "filedAt": "2026-06-18",
     "form": "424B4"
    },
    {
     "kind": "sec_s1",
     "url": "https://www.sec.gov/Archives/edgar/data/2123613/000119312526239298/d107928ds1.htm",
     "accession": "0001193125-26-239298",
     "quote": "We anticipate sharing topline data from the Phase 2b portion of KARDINAL-ASH in the first half of 2027.",
     "fetchedAt": "2026-11-12T05:58:06.935Z",
     "filedAt": "2026-05-26",
     "form": "S-1"
    },
    {
     "kind": "sec_s1",
     "url": "https://www.sec.gov/Archives/edgar/data/2123613/000119312526239298/d107928ds1.htm",
     "accession": "0001193125-26-239298",
     "quote": "We anticipate sharing Phase 2b topline data from KARDINAL-ASH in the first half of 2027.",
     "fetchedAt": "2026-11-12T05:58:06.935Z",
     "filedAt": "2026-05-26",
     "form": "S-1"
    }
   ],
   "firstSeen": "2026-05-26",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "confidence": 0.76,
   "pageUrl": "https://sec-api.dev/pdufa/tonlamarsen"
  },
  {
   "id": "nct07548632-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "licaminlimab",
   "companyCik": "0001953530",
   "ticker": "OCS",
   "indication": "Dry Eye Disease (DED)",
   "phase": "2/3",
   "sponsorName": "Oculis",
   "title": "PREDICT-1: A Clinical Study Evaluating Licaminlimab for Dry Eye Disease",
   "nctId": "NCT07548632",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07548632",
     "quote": "NCT07548632 (A Clinical Study Evaluating Licaminlimab for Dry Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Oculis.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/licaminlimab"
  },
  {
   "id": "nct07645248-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "hfa-152a",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Asthma",
   "phase": "3",
   "sponsorName": "GlaxoSmithKline",
   "title": "A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)",
   "nctId": "NCT07645248",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07645248",
     "quote": "NCT07645248 (A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/hfa-152a"
  },
  {
   "id": "nct07832552-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "triesence-triamcinolone-acetonide-injectable-suspension",
   "companyCik": "0001360214",
   "ticker": "HROW",
   "indication": "Postoperative Ocular Inflammation; Postoperative Ocular Pain",
   "phase": "3",
   "sponsorName": "Harrow Inc",
   "title": "A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery",
   "nctId": "NCT07832552",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07832552",
     "quote": "NCT07832552 (A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Harrow Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/triesence-triamcinolone-acetonide-injectable-suspension"
  },
  {
   "id": "nct07832552-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "triesence-triamcinolone-acetonide-injectable-suspension",
   "companyCik": "0001360214",
   "ticker": "HROW",
   "indication": "Postoperative Ocular Inflammation; Postoperative Ocular Pain",
   "phase": "3",
   "sponsorName": "Harrow Inc",
   "title": "A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery",
   "nctId": "NCT07832552",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07832552",
     "quote": "NCT07832552 (A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Harrow Inc.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/triesence-triamcinolone-acetonide-injectable-suspension"
  },
  {
   "id": "nct07837726-primary-completion",
   "type": "trial_completion_primary",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "tti-0102-cysteamine-pantetheine-disulfide",
   "companyCik": "0001877778",
   "ticker": "TTIPF",
   "indication": "Nephropathic Cystinosis; Cystinosis",
   "phase": "2",
   "sponsorName": "Thiogenesis Therapeutics, Inc.",
   "title": "Pilot Study of TTI-0102 in Cystinosis",
   "nctId": "NCT07837726",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07837726",
     "quote": "NCT07837726 (Pilot Study of TTI-0102 in Cystinosis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Thiogenesis Therapeutics, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/tti-0102-cysteamine-pantetheine-disulfide"
  },
  {
   "id": "nct07837726-readout",
   "type": "readout_topline",
   "window": {
    "start": "2026-12-01",
    "end": "2027-03-31",
    "label": "Dec 2026 to Mar 2027"
   },
   "dateConfidence": "quarter",
   "drugId": "tti-0102-cysteamine-pantetheine-disulfide",
   "companyCik": "0001877778",
   "ticker": "TTIPF",
   "indication": "Nephropathic Cystinosis; Cystinosis",
   "phase": "2",
   "sponsorName": "Thiogenesis Therapeutics, Inc.",
   "title": "Pilot Study of TTI-0102 in Cystinosis",
   "nctId": "NCT07837726",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07837726",
     "quote": "NCT07837726 (Pilot Study of TTI-0102 in Cystinosis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Thiogenesis Therapeutics, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "note": "Expected window: primary completion date plus three months, derived from the registry record; not a company-announced date.",
   "pageUrl": "https://sec-api.dev/pdufa/tti-0102-cysteamine-pantetheine-disulfide"
  },
  {
   "id": "nct07029711-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-02",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "ritlecitinib-higher-dose",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Severe Alopecia Areata",
   "phase": "3",
   "sponsorName": "Pfizer",
   "title": "B7981027: A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata",
   "nctId": "NCT07029711",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07029711",
     "quote": "NCT07029711 (A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-02 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/ritlecitinib-higher-dose"
  },
  {
   "id": "6c777be46583c4aa",
   "type": "pdufa",
   "dateConfidence": "exact",
   "date": "2026-12-03",
   "drugId": "zanzalintinib",
   "companyCik": "0000939767",
   "ticker": "EXEL",
   "indication": "previously treated metastatic colorectal cancer",
   "phase": "3",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm",
     "accession": "0000939767-26-000058",
     "quote": "\"Our first New Drug Application for zanzalintinib, for its initial potential indication in previously treated metastatic colorectal cancer, was accepted by U.S. regulatory authorities and is under active review, with a target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:58:26.959Z",
     "filedAt": "2026-05-05",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm",
     "accession": "0000939767-26-000059",
     "quote": "•In February 2026, we announced that the FDA accepted our NDA for zanzalintinib in combination with atezolizumab for the treatment of previously treated metastatic colorectal cancer, based on positive results from the STELLAR-303 phase 3 pivotal trial, and had assigned a standard review, with a PDUFA target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:58:26.947Z",
     "filedAt": "2026-05-05",
     "form": "10-Q"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000096/exel20260630exhibit991.htm",
     "accession": "0000939767-26-000096",
     "quote": "The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:57:51.184Z",
     "filedAt": "2026-08-05",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm",
     "accession": "0000939767-26-000058",
     "quote": "The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:58:26.959Z",
     "filedAt": "2026-05-05",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000019/exel2025q42025exhibit991.htm",
     "accession": "0000939767-26-000019",
     "quote": "The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:59:29.020Z",
     "filedAt": "2026-02-10",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000116/exel-20261002.htm",
     "accession": "0000939767-26-000116",
     "quote": "In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:57:20.906Z",
     "filedAt": "2026-10-29",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000098/exel-20260703.htm",
     "accession": "0000939767-26-000098",
     "quote": "In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:57:51.123Z",
     "filedAt": "2026-08-05",
     "form": "10-Q"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000059/exel-20260403.htm",
     "accession": "0000939767-26-000059",
     "quote": "Table of Contents that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:58:26.947Z",
     "filedAt": "2026-05-05",
     "form": "10-Q"
    },
    {
     "kind": "sec_10k",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm",
     "accession": "0000939767-26-000021",
     "quote": "In January 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:59:28.948Z",
     "filedAt": "2026-02-10",
     "form": "10-K"
    },
    {
     "kind": "sec_10k",
     "url": "https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm",
     "accession": "0000939767-26-000021",
     "quote": "In January 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a PDUFA target action date of December 3, 2026.",
     "fetchedAt": "2026-11-12T05:59:28.948Z",
     "filedAt": "2026-02-10",
     "form": "10-K"
    }
   ],
   "firstSeen": "2026-02-10",
   "lastSeen": "2026-10-29",
   "confidence": 0.96,
   "supersededBy": "a033df2f68881a62",
   "pageUrl": "https://sec-api.dev/pdufa/zanzalintinib"
  },
  {
   "id": "nct06421636-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-03",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "regn7999",
   "companyCik": "0000872589",
   "ticker": "REGN",
   "indication": "Non-Transfusion Dependent Beta-Thalassemia (NTDT)",
   "phase": "2",
   "sponsorName": "Regeneron Pharmaceuticals",
   "title": "FERVENT-1: A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body",
   "nctId": "NCT06421636",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06421636",
     "quote": "NCT06421636 (A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/regn7999"
  },
  {
   "id": "nct06991556-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-03",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "luxdegalutamide",
   "companyCik": "0001114448",
   "ticker": "NVS",
   "indication": "Metastatic Hormone-sensitive Prostate Cancer",
   "phase": "2",
   "sponsorName": "Novartis Pharmaceuticals",
   "title": "An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
   "nctId": "NCT06991556",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06991556",
     "quote": "NCT06991556 (An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/luxdegalutamide"
  },
  {
   "id": "nct07500506-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-04",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "vla15",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Lyme Disease",
   "phase": "3",
   "sponsorName": "Pfizer",
   "title": "A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine",
   "nctId": "NCT07500506",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07500506",
     "quote": "NCT07500506 (A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-04 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/vla15"
  },
  {
   "id": "nct06724809-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-07",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "eculizumab",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "NMOSD; Neuromyelitis Optica Spectrum Disorders",
   "phase": "3",
   "sponsorName": "Alexion Pharmaceuticals, Inc.",
   "title": "ECU-NMO-304: Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD",
   "nctId": "NCT06724809",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06724809",
     "quote": "NCT06724809 (Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-07 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/eculizumab"
  },
  {
   "id": "nct05757869-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-08",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "milvexian",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Atrial Fibrillation",
   "phase": "3",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "LIBREXIA-AF: A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation",
   "nctId": "NCT05757869",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05757869",
     "quote": "NCT05757869 (A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/milvexian"
  },
  {
   "id": "nct07228390-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-08",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "ritlecitinib",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Hidradenitis Suppurativa",
   "phase": "2",
   "sponsorName": "Pfizer",
   "title": "A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.",
   "nctId": "NCT07228390",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07228390",
     "quote": "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/ritlecitinib"
  },
  {
   "id": "nct06126224-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-09",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "karxt",
   "companyCik": "0000014272",
   "ticker": "BMY",
   "indication": "Psychosis Associated With Alzheimer's Disease",
   "phase": "3",
   "sponsorName": "Karuna Therapeutics, Inc., a Bristol Myers Squibb company",
   "title": "A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)",
   "nctId": "NCT06126224",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06126224",
     "quote": "NCT06126224 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-09 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/karxt"
  },
  {
   "id": "nct07222917-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-10",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "baxdrostat-dapagliflozin",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "Chronic Kidney Disease and Hypertension",
   "phase": "2",
   "sponsorName": "AstraZeneca",
   "title": "BaxDuo-Baltic: A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.",
   "nctId": "NCT07222917",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07222917",
     "quote": "NCT07222917 (A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-10 (ESTIMATED); Lead Sponsor AstraZeneca.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/baxdrostat-dapagliflozin"
  },
  {
   "id": "nct03441113-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-11",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "momelotinib",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Primary Myelofibrosis",
   "phase": "2",
   "sponsorName": "GlaxoSmithKline",
   "title": "Extended Access of Momelotinib in Adults With Myelofibrosis",
   "nctId": "NCT03441113",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT03441113",
     "quote": "NCT03441113 (Extended Access of Momelotinib in Adults With Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/momelotinib"
  },
  {
   "id": "nct04879329-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-11",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "disitamab-vedotin",
   "companyCik": "0000078003",
   "ticker": "PFE",
   "indication": "Urothelial Carcinoma",
   "phase": "2",
   "sponsorName": "Seagen, a wholly owned subsidiary of Pfizer",
   "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2",
   "nctId": "NCT04879329",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT04879329",
     "quote": "NCT04879329 (A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/disitamab-vedotin"
  },
  {
   "id": "c7a3acc7af5ba3be",
   "type": "pdufa",
   "dateConfidence": "exact",
   "date": "2026-12-12",
   "drugId": "imsidolimab",
   "companyCik": "0001347178",
   "ticker": "VNDA",
   "status": "scheduled",
   "sources": [
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm",
     "accession": "0001628280-26-053308",
     "quote": "•QuimilzaTM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026",
     "fetchedAt": "2026-11-12T05:57:52.685Z",
     "filedAt": "2026-08-05",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda8-k562026exhibit991.htm",
     "accession": "0001628280-26-031241",
     "quote": "•Imsidolimab BLA for Generalized Pustular Psoriasis accepted for FDA review; PDUFA target action date of December 12, 2026",
     "fetchedAt": "2026-11-12T05:58:26.263Z",
     "filedAt": "2026-05-06",
     "form": "8-K"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda8-k562026exhibit991.htm",
     "accession": "0001628280-26-031241",
     "quote": "•The FDA accepted the Biologics License Application (BLA) for imsidolimab in Generalized Pustular Psoriasis (GPP) with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026.",
     "fetchedAt": "2026-11-12T05:58:26.263Z",
     "filedAt": "2026-05-06",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1347178/000162828026031667/vnda-20260331.htm",
     "accession": "0001628280-26-031667",
     "quote": "•The FDA accepted the Biologics License Application (BLA) for imsidolimab in Generalized Pustular Psoriasis (GPP) with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026.",
     "fetchedAt": "2026-11-12T05:58:24.258Z",
     "filedAt": "2026-05-07",
     "form": "10-Q"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm",
     "accession": "0001193125-26-219500",
     "quote": "FDA target action date (PDUFA) of Dec. 12, 2026 for imsidolimab in generalized pustular psoriasis (GPP)",
     "fetchedAt": "2026-11-12T05:58:15.586Z",
     "filedAt": "2026-05-12",
     "form": "8-K",
     "cik": "0001370053"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm",
     "accession": "0001193125-26-088239",
     "quote": "FDA accepted the BLA filing for imsidolimab in generalized pustular psoriasis (GPP) in Feb. 2026 with a target action date of Dec. 12, 2026",
     "fetchedAt": "2026-11-12T05:59:11.225Z",
     "filedAt": "2026-03-03",
     "form": "8-K",
     "cik": "0001370053"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm",
     "accession": "0001193125-26-219515",
     "quote": "The FDA accepted the BLA filing for imsidolimab in GPP in February 2026 with a target action date of December 12, 2026.",
     "fetchedAt": "2026-11-12T05:58:15.583Z",
     "filedAt": "2026-05-12",
     "form": "10-Q",
     "cik": "0001370053"
    },
    {
     "kind": "sec_10k",
     "url": "https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/anab-20251231.htm",
     "accession": "0001193125-26-088290",
     "quote": "The FDA accepted the BLA filing for imsidolimab in GPP in February 2026 with a target action date of December 12, 2026.",
     "fetchedAt": "2026-11-12T05:59:11.223Z",
     "filedAt": "2026-03-03",
     "form": "10-K",
     "cik": "0001370053"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1370053/000119312526458461/anab-ex99_1.htm",
     "accession": "0001193125-26-458461",
     "quote": "FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP)",
     "fetchedAt": "2026-11-13T11:21:50.696Z",
     "filedAt": "2026-11-12",
     "form": "8-K",
     "cik": "0001370053"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1370053/000119312526458494/anab-20260930.htm",
     "accession": "0001193125-26-458494",
     "quote": "The FDA accepted the BLA filing for Quimilza in GPP in February 2026 with a target action date of December 12, 2026.",
     "fetchedAt": "2026-11-13T11:20:36.521Z",
     "filedAt": "2026-11-12",
     "form": "10-Q",
     "cik": "0001370053"
    },
    {
     "kind": "sec_ex99",
     "url": "https://www.sec.gov/Archives/edgar/data/1347178/000162828026067886/vnda8-k10282026exhibit991.htm",
     "accession": "0001628280-26-067886",
     "quote": "•The Biologics License Application (BLA) for Quimilza™ in Generalized Pustular Psoriasis (GPP) is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026.",
     "fetchedAt": "2026-11-12T05:57:21.774Z",
     "filedAt": "2026-10-28",
     "form": "8-K"
    },
    {
     "kind": "sec_10q",
     "url": "https://www.sec.gov/Archives/edgar/data/1347178/000134717826000002/vnda-20260930.htm",
     "accession": "0001347178-26-000002",
     "quote": "•The Biologics License Application (BLA) for Quimilza™ in Generalized Pustular Psoriasis (GPP) is under review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of December 12, 2026.",
     "fetchedAt": "2026-11-12T05:57:21.412Z",
     "filedAt": "2026-10-29",
     "form": "10-Q"
    }
   ],
   "firstSeen": "2026-03-03",
   "lastSeen": "2026-11-12",
   "confidence": 0.96,
   "mentionedBy": [
    "0001370053"
   ],
   "pageUrl": "https://sec-api.dev/pdufa/imsidolimab"
  },
  {
   "id": "nct06122779-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-14",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "bms-986435",
   "companyCik": "0000014272",
   "ticker": "BMY",
   "indication": "Heart Failure",
   "phase": "2",
   "sponsorName": "Bristol-Myers Squibb",
   "title": "AURORA-HFpEF: Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)",
   "nctId": "NCT06122779",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06122779",
     "quote": "NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/bms-986435"
  },
  {
   "id": "nct06317311-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-14",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "dostarlimab",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Carcinoma",
   "phase": "2",
   "sponsorName": "GlaxoSmithKline",
   "title": "RUBY-J: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer",
   "nctId": "NCT06317311",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06317311",
     "quote": "NCT06317311 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/dostarlimab"
  },
  {
   "id": "nct06430866-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-14",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "abp-234",
   "companyCik": "0000318154",
   "ticker": "AMGN",
   "indication": "Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)",
   "phase": "3",
   "sponsorName": "Amgen",
   "title": "Eucalyptus: Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)",
   "nctId": "NCT06430866",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06430866",
     "quote": "NCT06430866 (Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Amgen.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/abp-234"
  },
  {
   "id": "nct06806137-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-14",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "pcv-20",
   "companyCik": "0001131399",
   "ticker": "GSK",
   "indication": "Chickenpox",
   "phase": "3",
   "sponsorName": "GlaxoSmithKline",
   "title": "A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age",
   "nctId": "NCT06806137",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06806137",
     "quote": "NCT06806137 (A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/pcv-20"
  },
  {
   "id": "nct07184632-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-14",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "nnc0662-0419",
   "companyCik": "0000353278",
   "ticker": "NVO",
   "indication": "Overweight; Obesity",
   "phase": "2",
   "sponsorName": "Novo Nordisk A/S",
   "title": "A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity",
   "nctId": "NCT07184632",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07184632",
     "quote": "NCT07184632 (A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/nnc0662-0419"
  },
  {
   "id": "nct05327114-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-15",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "nipocalimab",
   "companyCik": "0000200406",
   "ticker": "JNJ",
   "indication": "Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",
   "phase": "2/3",
   "sponsorName": "Janssen Research & Development, LLC",
   "title": "Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",
   "nctId": "NCT05327114",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05327114",
     "quote": "NCT05327114 (Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/nipocalimab"
  },
  {
   "id": "nct05678673-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-15",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "xl092",
   "companyCik": "0000939767",
   "ticker": "EXEL",
   "indication": "Non-Clear Cell Renal Cell Carcinoma",
   "phase": "3",
   "sponsorName": "Exelixis",
   "title": "STELLAR-304: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma",
   "nctId": "NCT05678673",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT05678673",
     "quote": "NCT05678673 (Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Exelixis.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/xl092"
  },
  {
   "id": "nct06607627-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-15",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "drugId": "gefurulimab",
   "companyCik": "0000901832",
   "ticker": "AZN",
   "indication": "Generalized Myasthenia Gravis; gMG",
   "phase": "3",
   "sponsorName": "Alexion Pharmaceuticals, Inc.",
   "title": "PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis",
   "nctId": "NCT06607627",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT06607627",
     "quote": "NCT06607627 (PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc..",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/pdufa/gefurulimab"
  },
  {
   "id": "nct07015437-primary-completion",
   "type": "trial_completion_primary",
   "date": "2026-12-15",
   "window": {
    "start": "2026-12-01",
    "end": "2026-12-31",
    "label": "December 2026"
   },
   "dateConfidence": "month",
   "companyCik": "0001020214",
   "ticker": "CERS",
   "indication": "Healthy Subjects",
   "phase": "2",
   "sponsorName": "Cerus Corporation",
   "title": "A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1",
   "nctId": "NCT07015437",
   "status": "scheduled",
   "sources": [
    {
     "kind": "ctgov",
     "url": "https://clinicaltrials.gov/study/NCT07015437",
     "quote": "NCT07015437 (A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Cerus Corporation.",
     "fetchedAt": "2026-11-16T10:21:02.081Z"
    }
   ],
   "firstSeen": "2026-11-12T03:44:55.771Z",
   "lastSeen": "2026-11-16T10:20:01.158Z",
   "pageUrl": "https://sec-api.dev/companies/cers/catalysts"
  }
 ]
}